Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12959 clinical trials for this condition and its sub-types, 151 tagged with Immune system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Immune system disorder
-
Autoimmune disease 313 trials · 4,033 incl. sub-types
47 sub-types
- Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types Sub-types →
- Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types Sub-types →
- Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types Sub-types →
- CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types Sub-types →
- Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types Sub-types →
- Lupus erythematosus 39 trials · 548 incl. sub-types Sub-types →
- Scleroderma 47 trials · 305 incl. sub-types Sub-types →
- Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types Sub-types →
- Autoimmune disorder of blood 0 trials · 152 incl. sub-types Sub-types →
- Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types Sub-types →
- Vitiligo 100 trials Sub-types →
- Antiphospholipid syndrome 58 trials · 59 incl. sub-types Sub-types →
- Autoimmune bullous skin disease 7 trials · 55 incl. sub-types Sub-types →
- Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types Sub-types →
- Rheumatic fever 16 trials
- Overlapping connective tissue disease 2 trials · 15 incl. sub-types Sub-types →
- Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types Sub-types →
- Undifferentiated connective tissue syndrome 7 trials
- Autoimmune pulmonary alveolar proteinosis 6 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Anti-glomerular basement membrane disease 5 trials
- Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types Sub-types →
- Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types Sub-types →
- Cryoglobulinemia 3 trials Sub-types →
- Susac syndrome 2 trials
- Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types Sub-types →
- Anti-neutrophil antibody associated vasculitis 1 trial
- Phacolytic glaucoma 1 trial
- Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types Sub-types →
- Jaccoud syndrome 0 trials
- Kimura disease 0 trials
- Reynolds syndrome 0 trials
- Autoerythrocyte sensitization syndrome 0 trials
- Autoimmune disease with susceptibility to mycobacterium tuberculosis 0 trials
- Autoimmune glomerulonephritis 0 trials
- Autoimmune pulmonary disease due to PD-1 deficiency 0 trials
- Autoimmune urticaria 0 trials
- Euthyroid Graves orbitopathy 0 trials
- Multisystem autoimmune disease due to IKAROS gain of function 0 trials
- Non-specific autoimmune brainstem encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune brainstem encephalitis without characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia with characteristic antibodies 0 trials
- Non-specific autoimmune cerebellar ataxia without characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis with characteristic antibodies 0 trials
- Non-specific autoimmune supratentorial encephalitis without characteristic antibodies 0 trials
- Tempi syndrome 0 trials
- Type II hypersensitivity reaction disease 0 trials
-
Leukocyte disorder 6 trials · 3,572 incl. sub-types
23 sub-types
- B-cell neoplasm 304 trials · 3,167 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Leukopenia 6 trials · 78 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- Eosinophil disorder 2 trials · 51 incl. sub-types Sub-types →
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Functional neutrophil defect 0 trials · 13 incl. sub-types Sub-types →
- Mast cell activation syndrome 8 trials · 9 incl. sub-types Sub-types →
- POEMS syndrome 8 trials
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Thymoma type B 0 trials · 4 incl. sub-types Sub-types →
- Human granulocytic anaplasmosis 1 trial
- Pelger-Huet anomaly 0 trials
- Eosinophil peroxidase deficiency 0 trials
- Hereditary neutrophilia 0 trials
- Human monocytic ehrlichiosis 0 trials
- Leukostasis 0 trials
- Pituitary gland basophil adenoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
-
Immune system cancer 0 trials · 3,121 incl. sub-types
25 sub-types
- Bone marrow cancer 2 trials · 1,631 incl. sub-types Sub-types →
- Plasma cell myeloma 1,105 trials · 1,128 incl. sub-types Sub-types →
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Lymphatic system cancer 4 trials · 69 incl. sub-types Sub-types →
- Dendritic cell sarcoma 0 trials · 53 incl. sub-types Sub-types →
- B-cell childhood acute lymphoblastic leukemia 37 trials
- T-cell childhood acute lymphocytic leukemia 10 trials
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Subcutaneous panniculitis-like T-cell lymphoma 8 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- Indolent primary cutaneous B-cell lymphoma 1 trial · 2 incl. sub-types Sub-types →
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
- Breast diffuse large B-cell lymphoma 1 trial
- Colon Burkitt lymphoma 0 trials
- Colorectal diffuse large B-cell lymphoma 0 trials
- Gastric mantle cell lymphoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Mast cell sarcoma 0 trials
- Primary pulmonary diffuse large B-cell lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
- Small intestinal diffuse large B-cell lymphoma 0 trials
- Small intestinal enteropathy-associated T-cell lymphoma 0 trials
- Solitary plasmacytoma of chest wall 0 trials
- Thyroid gland diffuse large B-cell lymphoma 0 trials
-
Bone marrow disorder 18 trials · 1,761 incl. sub-types
7 sub-types
- Bone marrow neoplasm 3 trials · 1,631 incl. sub-types Sub-types →
- Polycythemia 9 trials · 99 incl. sub-types Sub-types →
- Bone marrow failure syndrome 48 trials Sub-types →
- Osteomyelitis 43 trials · 46 incl. sub-types Sub-types →
- Fanconi anemia 29 trials · 42 incl. sub-types Sub-types →
- Drachtman Weinblatt Sitarz syndrome 0 trials
- Premature ovarian failure 15 0 trials
-
Inflammatory bowel disease 429 trials · 1,079 incl. sub-types
40 sub-types
- Colitis 41 trials · 677 incl. sub-types Sub-types →
- Crohn disease 561 trials · 567 incl. sub-types Sub-types →
- Proctitis 2 trials · 21 incl. sub-types Sub-types →
- Inflammatory bowel disease 1 3 trials
- Undetermined colitis 3 trials
- Ulcerative proctosigmoiditis 2 trials
- ALPI-related inflammatory bowel disease 0 trials
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- TRIM22-related inflammatory bowel disease 0 trials
- Cap polyposis 0 trials
- Cutaneous photosensitivity-lethal colitis syndrome 0 trials
- Inflammatory bowel disease (infantile ulcerative colitis) 31, autosomal recessive 0 trials
- Inflammatory bowel disease 10 0 trials
- Inflammatory bowel disease 11 0 trials
- Inflammatory bowel disease 12 0 trials
- Inflammatory bowel disease 13 0 trials
- Inflammatory bowel disease 14 0 trials
- Inflammatory bowel disease 15 0 trials
- Inflammatory bowel disease 16 0 trials
- Inflammatory bowel disease 17 0 trials
- Inflammatory bowel disease 18 0 trials
- Inflammatory bowel disease 19 0 trials
- Inflammatory bowel disease 2 0 trials
- Inflammatory bowel disease 20 0 trials
- Inflammatory bowel disease 21 0 trials
- Inflammatory bowel disease 22 0 trials
- Inflammatory bowel disease 23 0 trials
- Inflammatory bowel disease 24 0 trials
- Inflammatory bowel disease 26 0 trials
- Inflammatory bowel disease 27 0 trials
- Inflammatory bowel disease 29 0 trials
- Inflammatory bowel disease 3 0 trials
- Inflammatory bowel disease 30 0 trials
- Inflammatory bowel disease 4 0 trials
- Inflammatory bowel disease 5 0 trials
- Inflammatory bowel disease 6 0 trials
- Inflammatory bowel disease 7 0 trials
- Inflammatory bowel disease 8 0 trials
- Inflammatory bowel disease 9 0 trials
- Neonatal inflammatory skin and bowel disease 0 trials Sub-types →
-
Hypersensitivity reaction disease 32 trials · 1,022 incl. sub-types
10 sub-types
- Allergic disease 178 trials · 966 incl. sub-types Sub-types →
- Anaphylaxis 26 trials · 27 incl. sub-types Sub-types →
- Type IV hypersensitivity disease 0 trials · 18 incl. sub-types Sub-types →
- Hypersensitivity vasculitis 0 trials · 16 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- IgE responsiveness, atopic 9 trials
- Type III hypersensitivity disease 3 trials · 6 incl. sub-types Sub-types →
- Progestogen hypersensitivity 3 trials
- Pseudoallergy 0 trials Sub-types →
- Type II hypersensitivity reaction disease 0 trials
-
Immunodeficiency disease 55 trials · 776 incl. sub-types
95 sub-types
- T-cell immunodeficiency 4 trials · 484 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Myalgic encephalomeyelitis/chronic fatigue syndrome 73 trials
- Combined immunodeficiency 3 trials · 57 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types Sub-types →
- GATA2 deficiency with susceptibility to MDS/AML 5 trials · 8 incl. sub-types Sub-types →
- Idiopathic CD4 lymphocytopenia 7 trials
- IKBKG-related immunodeficiency with or without ectodermal dysplasia 0 trials · 4 incl. sub-types Sub-types →
- Immunodeficiency due to selective anti-polysaccharide antibody deficiency 2 trials
- IRF4-related immune disorder 1 trial Sub-types →
- PTEN harmartoma tumor syndrome with immune disorder 1 trial
- Immunodeficiency 23 1 trial
- Immunodeficiency 31B 1 trial
- DNAJC21-related Shwachman Diamond syndrome 0 trials
- DOCK2 deficiency 0 trials
- FADD-related immunodeficiency 0 trials
- FASLG-related immunodeficiency 0 trials
- FNIP1-associated syndrome 0 trials
- Shwachman-Diamond syndrome 1 0 trials
- TFRC-related combined immunodeficiency 0 trials
- TNFRSF9-related immunodeficiency 0 trials Sub-types →
- Wiskott-Aldrich syndrome 2 0 trials
- Wiskott-Aldrich syndrome, autosomal dominant form 0 trials
- Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 0 trials
- Chronic mucocutaneous candidiasis and connective tissue disease due to JNK1 haploinsufficiency 0 trials
- Cryptosporidiosis-chronic cholangitis-liver disease syndrome 0 trials
- Hatipoglu immunodeficiency syndrome 0 trials
- Hypoproteinemia, hypercatabolic 0 trials
- Immune deficiency due to impaired neutrophil phagocytosis and migration 0 trials
- Immunodeficiency 101 (varicella zoster virus-specific) 0 trials
- Immunodeficiency 102 0 trials
- Immunodeficiency 106, susceptibility to viral infections 0 trials
- Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection 0 trials
- Immunodeficiency 112 0 trials
- Immunodeficiency 113 with autoimmunity and autoinflammation 0 trials
- Immunodeficiency 114, folate-responsive 0 trials
- Immunodeficiency 115 with autoinflammation 0 trials
- Immunodeficiency 117 0 trials
- Immunodeficiency 118 0 trials
- Immunodeficiency 119 0 trials
- Immunodeficiency 11b with atopic dermatitis 0 trials
- Immunodeficiency 121 with autoinflammation 0 trials
- Immunodeficiency 122 0 trials
- Immunodeficiency 123 with HPV-related verrucosis 0 trials
- Immunodeficiency 125 0 trials
- Immunodeficiency 126, susceptibility to 0 trials
- Immunodeficiency 127 0 trials
- Immunodeficiency 128 0 trials
- Immunodeficiency 132b 0 trials
- Immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy 0 trials
- Immunodeficiency 134 (Epstein-Barr virus-specific) 0 trials
- Immunodeficiency 14b, autosomal recessive 0 trials
- Immunodeficiency 15a 0 trials
- Immunodeficiency 35 0 trials
- Immunodeficiency 45 0 trials
- Immunodeficiency 53 0 trials
- Immunodeficiency 57 0 trials
- Immunodeficiency 60 0 trials
- Immunodeficiency 62 0 trials
- Immunodeficiency 63 with lymphoproliferation and autoimmunity 0 trials
- Immunodeficiency 64 0 trials
- Immunodeficiency 65, susceptibility to viral infections 0 trials
- Immunodeficiency 66 0 trials
- Immunodeficiency 67 0 trials
- Immunodeficiency 69 0 trials
- Immunodeficiency 70 0 trials
- Immunodeficiency 72 with autoinflammation 0 trials
- Immunodeficiency 74, COVID-19-related, X-linked 0 trials
- Immunodeficiency 75 0 trials
- Immunodeficiency 76 0 trials
- Immunodeficiency 77 0 trials
- Immunodeficiency 78 with autoimmunity and developmental delay 0 trials
- Immunodeficiency 80 with or without congenital cardiomyopathy 0 trials
- Immunodeficiency 81 0 trials
- Immunodeficiency 82 with systemic inflammation 0 trials
- Immunodeficiency 84 0 trials
- Immunodeficiency 85 and autoimmunity 0 trials
- Immunodeficiency 86 0 trials
- Immunodeficiency 87 and autoimmunity 0 trials
- Immunodeficiency 88 0 trials
- Immunodeficiency 89 and autoimmunity 0 trials
- Immunodeficiency 91 and hyperinflammation 0 trials
- Immunodeficiency 92 0 trials
- Immunodeficiency 93 and hypertrophic cardiomyopathy 0 trials
- Immunodeficiency 95 0 trials
- Immunodeficiency 96 0 trials
- Immunodeficiency 97 with autoinflammation 0 trials
- Immunodeficiency 98 with autoinflammation, X-linked 0 trials
- Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias 0 trials
- Immunodeficiency due to CD25 deficiency 0 trials
- Lymphoproliferative syndrome 1 0 trials
- Primary immunodeficiency due to calcium channel deficiency 0 trials
- Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency 0 trials
- Pyogenic bacterial infections due to MyD88 deficiency 0 trials
-
Lymphoid system disorder 1 trial · 744 incl. sub-types
5 sub-types
- Lymphatic system disorder 30 trials · 707 incl. sub-types Sub-types →
- Tonsillitis 23 trials · 27 incl. sub-types Sub-types →
- Waldeyer's ring cancer 0 trials · 8 incl. sub-types Sub-types →
- Tonsil neoplasm 0 trials · 8 incl. sub-types Sub-types →
- Peritonsillar abscess 4 trials
-
Psoriasis 379 trials
3 sub-types
- Pustular psoriasis 6 trials · 39 incl. sub-types Sub-types →
- Guttate psoriasis 2 trials
- Psoriasis 2 0 trials
-
Inborn error of immunity 121 trials · 343 incl. sub-types
40 sub-types
- Lymphoproliferative syndrome 69 trials · 99 incl. sub-types Sub-types →
- B cell deficiency 5 trials · 85 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Complement deficiency 2 trials · 28 incl. sub-types Sub-types →
- Hereditary hemophagocytic lymphohistiocytosis 8 trials · 16 incl. sub-types Sub-types →
- Aicardi-Goutieres syndrome 9 trials Sub-types →
- Familial isolated congenital asplenia 6 trials
- Chronic mucocutaneous candidiasis 4 trials Sub-types →
- Immunoglobulin heavy chain deficiency 0 trials · 2 incl. sub-types Sub-types →
- A20 haploinsufficiency 1 trial
- BENTA disease 1 trial
- Immuno-osseous dysplasia 0 trials · 1 incl. sub-types Sub-types →
- Immunodysregulation with variable immunodeficiency and autoimmunity 1 trial
- IL10-related early-onset inflammatory bowel disease 0 trials Sub-types →
- NK cell deficiency 0 trials
- Say-Barber-Miller syndrome 0 trials
- T cell and NK cell immunodeficiency 0 trials
- T-cell immunodeficiency with epidermodysplasia verruciformis 0 trials
- X-linked immunoneurologic disorder 0 trials
- Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity 0 trials
- Combined immunodeficiency due to moesin deficiency 0 trials
- Combined immunodeficiency with faciooculoskeletal anomalies 0 trials
- Dendritic cell deficiency 0 trials
- Ectodermal dysplasia and immune deficiency 0 trials Sub-types →
- Hepatic veno-occlusive disease-immunodeficiency syndrome 0 trials
- Immune dysregulation with immunodeficiency due to AIOLOS haploinsufficiency 0 trials
- Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome 0 trials
- Immunodeficiency 28 0 trials
- Immunodeficiency 33 0 trials
- Immunodeficiency 37 0 trials Sub-types →
- Immunodeficiency 39 0 trials
- Immunodeficiency 47 0 trials
- Immunodeficiency 49 0 trials
- Immunodeficiency with defective T-cell response to interleukin 1 0 trials
- Immunodeficiency, X-linked, with deficiency of 115,000 Dalton surface glycoprotein 0 trials
- Inflammatory bowel disease-recurrent sinopulmonary infections syndrome 0 trials
- Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 0 trials
- Properdin deficiency, X-linked 0 trials
- Recurrent infections associated with rare immunoglobulin isotypes deficiency 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
-
Graft versus host disease 186 trials · 300 incl. sub-types
2 sub-types
- Chronic graft versus host disease 118 trials
- Acute graft versus host disease 86 trials
-
Thymus gland disorder 1 trial · 240 incl. sub-types
3 sub-types
- Thymus neoplasm 5 trials · 240 incl. sub-types Sub-types →
- Ectopic thymus 0 trials
- Thymic dysplasia 0 trials
-
Spondyloarthropathy 121 trials · 198 incl. sub-types
3 sub-types
- Ankylosing spondylitis 109 trials · 113 incl. sub-types Sub-types →
- Kummell disease 1 trial
- Hypermobility of coccyx 0 trials
-
Thrombocytopenic purpura 8 trials · 116 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types Sub-types →
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Phagocytic cell dysfunction 1 trial · 76 incl. sub-types
7 sub-types
- Langerhans cell histiocytosis 39 trials · 40 incl. sub-types Sub-types →
- Defective phagocytic cell engulfment 0 trials · 37 incl. sub-types Sub-types →
- Phagocyte bactericidal dysfunction 0 trials · 37 incl. sub-types Sub-types →
- Defective phagocytic cell chemotaxis 0 trials
- Defective phagocytic cell opsonization 0 trials
- Familial lipochrome histiocytosis 0 trials
- Phagocytosis, plasma-related defect 1N 0 trials
-
Cytokine release syndrome 33 trials
-
Immunoproliferative disorder 18 trials
-
Familial Mediterranean fever 15 trials
2 sub-types
-
Immunodeficiency-related disorder 1 trial · 15 incl. sub-types
1 sub-type
- AIDS-related disorder 3 trials · 14 incl. sub-types Sub-types →
-
Twin to twin transfusion syndrome 14 trials
1 sub-type
-
22q11.2 deletion syndrome 7 trials · 13 incl. sub-types
4 sub-types
- DiGeorge syndrome 11 trials
- Velocardiofacial syndrome 4 trials
- Chromosome 22q11.2 deletion syndrome, distal 0 trials
- Congenital unilateral hypoplasia of depressor anguli oris 0 trials
-
Cryopyrin-associated periodic syndrome 10 trials
3 sub-types
- CINCA syndrome 4 trials
- Muckle-Wells syndrome 3 trials
- Familial cold autoinflammatory syndrome 3 trials Sub-types →
-
Acquired immunodeficiency 5 trials
2 sub-types
- Good syndrome 0 trials
- Acquired adult-onset immunodeficiency 0 trials
-
Anti-HLA hyperimmunization 3 trials
-
6 sub-types
- Proteasome-associated autoinflammatory syndrome 1 1 trial
- Proteasome-associated autoinflammatory syndrome 2 0 trials
- Proteasome-associated autoinflammatory syndrome 3 0 trials
- Proteasome-associated autoinflammatory syndrome 4 0 trials
- Proteasome-associated autoinflammatory syndrome 5 0 trials
- Proteasome-associated autoinflammatory syndrome 6 0 trials
-
Roifman syndrome 1 trial
-
Aggressive insulitis 1 trial
-
Transcobalamin II deficiency 1 trial
-
CADINS disease 0 trials
-
Vici syndrome 0 trials
-
Autosomal recessive osteopetrosis 7 0 trials
-
Benign insulitis 0 trials
-
Cytokine receptor deficiency 0 trials
-
Epidermodysplasia verruciformis 0 trials
1 sub-type
-
Erythroderma desquamativum 0 trials
-
Immune system organ benign neoplasm 0 trials
3 sub-types
- Benign neoplasm of lymph node 0 trials
- Benign neoplasm of spleen 0 trials Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
Most studied deeper sub-types
Showing the 400 most recently updated of 2731 trials in this tab.
-
Rewriting the code: a One-Time gene fix for a rare immune disease?
Cure By invitation onlyThis trial tests a one-time gene therapy for WHIM syndrome, a rare inherited immune disorder that causes severe infections. Doctors collect a person's own blood stem cells, use base editing to correct the faulty CXCR4 gene, and return the edited cells to the body. The goal is to …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells target CS1 to fight stubborn myeloma
Cure OngoingResearchers are testing a new type of immune cell therapy called CS1-targeted CAR-T in adults with multiple myeloma that has come back or stopped responding to treatment. The study enrolls about 10 participants who have already received several lines of therapy. Doctors collect a…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Could a Half-Matched donor cure a rare immune disease?
Cure OngoingThis early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…
Early phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a Precision-Engineered transplant rebuild immunity in babies born without it?
Cure OngoingInfants with severe combined immunodeficiency (SCID) lack working immune cells and face life-threatening infections. A matched sibling donor transplant is the standard cure, but most babies do not have one. This trial tests a refined transplant using a parent or other partially m…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can a calming drug make cord blood transplants safer?
Cure PausedResearchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…
Phase 2 • Sponsor: Leland Metheny • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Supercharged immune cells take aim at cancer and viruses in one shot
Cure OngoingThis study tests a new type of immune cell therapy for people with CD19-positive leukemia or lymphoma who have had a stem cell transplant. The cells are specially designed to both recognize and kill cancer cells (through a CD19-targeting antibody) and fight three common viruses (…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Cure
Last updated Jul 16, 2026 00:00 UTC
-
New vaccine strategy could shield lymphoma survivors from pneumonia
Vaccine OngoingThis study looks at how well a pneumonia vaccine (PCV20) works in people who have recovered from B-cell lymphoma and were treated with anti-CD20 therapy. Researchers want to see if a single dose or a boosted dose is safer and more effective at preventing pneumococcal infections. …
Phase 4 • Sponsor: M.D. Anderson Cancer Center • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
New cocktail of drugs aimed at halting bone metastases in prostate cancer
Disease control PausedThis study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug riliprubart tested for Long-Term control of nerve disease CIDP
Disease control By invitation onlyThis study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving th…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New Three-Drug cocktail aims to tackle tough lymphomas
Disease control OngoingThis study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control PausedThis study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Real-World lupus drug study launches in poland
Disease control OngoingThis study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for seniors with aggressive blood cancer: targeted combo shows promise
Disease control OngoingThis study tests whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their ca…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug shows promise for Crohn's sufferers in Mid-Stage trial
Disease control OngoingThis study tests a new drug called AZD7798 in 120 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and improve the appearance of the gut lining. Participants are randomly assigned to receive either the drug or a placebo, and neither the…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control OngoingThis study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted drug shows promise for rare ROS1 cancers
Disease control OngoingThis study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in large trial
Disease control By invitation onlyThis study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard drug, azacitidine, for people with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to find the best dose and see if the combination can shrink or control the cancer. About 2…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to deepen remission in early CML
Disease control OngoingThis study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. …
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for chinese patients with severe transplant complication: ruxolitinib trial launches
Disease control OngoingThis study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patie…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to wipe out lingering leukemia before transplant
Disease control OngoingThis phase 2 trial tests whether a combination of venetoclax and azacitidine can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who still have or develop leftover cancer cells after initial chemotherapy, and before a stem cell transplant. Abou…
Phase 2 • Sponsor: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug iberdomide takes on lenalidomide in battle to keep myeloma at bay
Disease control OngoingThis phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two biologics go head to head in ulcerative colitis
Disease control OngoingResearchers compare two biologic drugs, ustekinumab and infliximab, in adults with moderate to severe ulcerative colitis who have not previously tried biologic therapy. The trial measures how well each drug reduces inflammation, controls symptoms, and improves quality of life, wh…
Sponsor: Helwan University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill hopes to boost blood in bone marrow disease
Disease control OngoingThis study tests an experimental drug, HT-6184, in adults with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take…
Phase 2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to keep multiple myeloma in check longer
Disease control OngoingThis phase 3 study tests whether adding daratumumab to the standard drug lenalidomide as maintenance therapy after a stem cell transplant can better control multiple myeloma. About 1,100 participants will be randomly assigned to receive either lenalidomide alone or lenalidomide p…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New daily pill could rival infusion for slowing progressive MS
Disease control OngoingThis phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New MS pill aims to outperform current treatment
Disease control OngoingThis Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take aim at CD70-Positive cancers in new trial
Disease control CancelledThis early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Crohn's: experimental drug targets gut inflammation
Disease control OngoingThis study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Partic…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug shows promise for Long-Term control of rare immune disorders
Disease control OngoingThis study is testing the long-term safety of a drug called leniolisib in people with primary immunodeficiency disorders linked to PI3K signaling. Participants are 12 people who already took leniolisib in a previous study and may benefit from continuing it. The goal is to see if …
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an HDAC inhibitor wipe out residual leukemia cells?
Disease control OngoingResearchers are studying whether the drug chidamide can help keep high-risk acute myeloid leukemia (AML) in remission when used as maintenance therapy. The trial enrolls adults with specific genetic features and measurable residual disease who are not receiving a stem cell transp…
Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control OngoingThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can myeloma treatment work without steroids?
Disease control OngoingResearchers are testing whether daratumumab and lenalidomide can treat newly diagnosed multiple myeloma without adding steroids. The trial enrolls patients who are not candidates for high-dose chemotherapy and have not received prior treatment. The goal is to see how often infusi…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Four-Drug cocktail aims to tackle tough myeloma
Disease control OngoingThis phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug may help lung damage after stem cell transplants
Disease control OngoingThis study tests a new oral drug called alvelestat (MPH966) in adults who have lung damage (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block an enzyme that may cause lung injury. The trial has two parts: first to find the safest and most eff…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New AI-Powered insulin system could free people with diabetes from constant meal calculations
Disease control OngoingThis study tests AIDANET, an automated insulin delivery algorithm, in 40 adults with type 1 diabetes. Participants will use the system in three modes: fully automatic (no meal announcements), hybrid (with meal announcements), or a mix. The goal is to see which mode keeps blood su…
Sponsor: Sue Brown • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cocktail targets tough lymphoma
Disease control OngoingThis early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in people with mantle cell lymphoma that has returned or not responded to prior treatment. The main goal is to find the safest dose of this combination by monitoring side effects. U…
Phase 1 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for older leukemia patients with gentler drug combo
Disease control OngoingThis study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia.…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Immune cell therapy takes on tough scleroderma
Disease control OngoingThis early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New stem cell approach aims to cure rare immune disease
Disease control OngoingThis study tests a high-dose stem cell transplant for people with chronic granulomatous disease (CGD), a condition that weakens the immune system. Participants receive donor stem cells along with drugs to prevent rejection and graft-versus-host disease. The goal is to improve tra…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a daily pill boost blood counts in fanconi anemia?
Disease control OngoingFanconi anemia is a genetic condition that can damage bone marrow and lead to low blood cell counts, causing anemia, bleeding, or infections. Researchers are testing whether a daily pill called eltrombopag can improve blood counts in people with this condition. The trial enrolls …
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise for leukemia patients
Disease control OngoingThis study tests a combination of four drugs (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV gene). The goal is to see if this combo can achieve…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Four-Drug combo aims to push High-Risk myeloma into deep remission
Disease control OngoingResearchers are testing whether adding selinexor to carfilzomib, daratumumab, and dexamethasone helps patients with high-risk multiple myeloma that has returned or stopped responding to treatment. Participants must have received one to three prior lines of therapy and be sensitiv…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New oral drug balinatunfib tested for long-term control of Crohn's and colitis
Disease control OngoingThis study looks at the long-term safety and effectiveness of balinatunfib, an oral tablet, in adults with Crohn's disease or ulcerative colitis. Participants have already completed a one-year treatment in a previous study. The trial will last up to 107 weeks and includes both do…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a skin cream bring back color to faces with vitiligo?
Disease control OngoingResearchers are testing a cream called delgocitinib on facial vitiligo, a condition where skin loses its color in patches. Twelve adults with non-segmental vitiligo on the face will apply the cream twice daily for 24 weeks. The trial measures changes in the size and severity of w…
Phase 2 • Sponsor: Lone Skov • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cocktail aims to keep myeloma at bay longer
Disease control OngoingThis phase 2 trial is testing whether adding the drug daratumumab to a standard treatment plan helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The study involves 50 participants and uses a combination of daratumumab, carfilzomib,…
Phase 2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Two-Drug chemo combo shrink BRCA breast tumors before surgery?
Disease control OngoingResearchers test whether giving mitomycin plus carboplatin before surgery helps people with BRCA1 or BRCA2 mutations and locally advanced triple-negative breast cancer. The trial compares this combination, followed by paclitaxel, against standard chemotherapy. About 30 adults wit…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New Two-Drug combo targets Hard-to-Treat myeloma in early trial
Disease control OngoingThis early-stage study is testing whether a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—is safe and tolerable for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial will enroll about 87 p…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug duo aims to control rare lymphoma without chemotherapy
Disease control OngoingThis study tests whether combining zanubrutinib (a targeted pill) with rituximab (an antibody infusion) can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes and organs. About 42 adults with newly diagnosed advanced disease or lymphoma that returned after …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Smart inhalers track Fasenra's asthma control over full dosing cycle
Disease control By invitation onlyThis study tracks people with severe eosinophilic asthma who already take Fasenra (benralizumab) every 8 weeks. Participants use electronic monitors on their regular inhalers and a study-provided rescue inhaler (AirSupra) to see if asthma control stays steady throughout the dosin…
Phase 4 • Sponsor: Endeavor Health • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Adult leukemia patients get Kid-Style chemo combo in new trial
Disease control OngoingThis phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatr…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Scientists probe whether lebrikizumab rewires diseased skin at the molecular level
Disease control OngoingResearchers are studying lebrikizumab, an approved injectable drug for atopic dermatitis, to understand how it changes skin biology over time. The trial enrolls 48 people with moderate-to-severe atopic dermatitis who have not done well on topical treatments. Participants receive …
Phase 4 • Sponsor: Johann E Gudjonsson MD PhD • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New antibody cocktail aims to tame ulcerative colitis for good
Disease control By invitation onlyThis study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …
Phase 2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill aims to tame rare immune diseases
Disease control OngoingThis early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Targeted pill takes aim at rare cancer mutations
Disease control OngoingThis phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New study tests which drug gives myeloma patients better daily life
Disease control OngoingThis phase 2 trial compares daratumumab and lenalidomide as maintenance therapy for people with newly diagnosed multiple myeloma who have responded well to initial treatment. The main goal is to see which drug provides better health-related quality of life, measured through quest…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New gene therapy aims to fix immune system in rare disease
Disease control By invitation onlyThis study tests a new gene therapy for people with chronic granulomatous disease (CGD), a genetic disorder that weakens the immune system and makes them prone to serious infections. The treatment takes the patient's own blood stem cells, adds a missing gene in the lab, and puts …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingThis study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New app helps teens with diabetes focus on what they do well
Disease control OngoingThis study tests a program called 'Type 1 Doing Well' for youth aged 10–13 with type 1 diabetes and their parents. The program uses a smartphone app, goal-setting, and family meetings to build on the teen's diabetes strengths. Researchers want to see if it improves blood sugar co…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New MS drug candidate enters early safety testing
Disease control OngoingThis early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in controlling Early-Stage leukemia
Disease control OngoingThis study tests a combination of two drugs, dasatinib and venetoclax, in people with early chronic phase chronic myeloid leukemia (CML). The goal is to see if the combination can better control the disease by blocking enzymes that help cancer cells grow. About 155 participants w…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triple-Target CAR T-Cells take on tough lymphomas
Disease control By invitation onlyThis early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…
Phase 1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for ulcerative colitis: phase 3 trial of afimkibart underway
Disease control OngoingThis Phase 3 trial tests whether the drug Afimkibart can help people with moderate-to-severe ulcerative colitis achieve remission. About 400 adults who have not responded well to other treatments will receive either Afimkibart or a placebo. The study measures remission at 12 and …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental drug combo targets brain cancer metabolism
Disease control OngoingThis early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug shows promise for rare blood cancer
Disease control OngoingThis phase 2 study tests acalabrutinib, a targeted drug, in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see how well the drug shrinks tumors and controls the disease. Participants either had prior treatment or are new to therapy and cannot t…
Phase 2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a daily ultrasound zap arthritis pain at home?
Disease control OngoingThis study tests a non-invasive device that uses ultrasound to stimulate the spleen and reduce inflammation in people with moderate to severe rheumatoid arthritis. About 60 adults who haven't responded well to standard medications will use the device at home for 12 weeks, with so…
Sponsor: SecondWave Systems Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for mantle cell lymphoma: transplant combo vs drug alone in major trial
Disease control OngoingThis study tests whether a stem cell transplant followed by the drug rituximab works better than rituximab alone for people with mantle cell lymphoma whose cancer is in first complete remission. About 689 adults aged 18 to 70 are taking part. The goal is to see which approach hel…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Robot-Assisted surgery for lung cancer and thymus disease put to the test
Disease control OngoingThis study is testing a new robotic surgery system, the da Vinci SP, for removing part or all of a lung (lobectomy) or the thymus gland (thymectomy) in people with lung cancer, benign lung disease, thymoma, or myasthenia gravis. The goal is to see if the robot can perform these s…
Sponsor: Intuitive Surgical • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug acalabrutinib takes on standard combo in untreated CLL
Disease control OngoingThis Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo shot could tame follicular lymphoma
Disease control OngoingThis study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Investigational drug AMG 335 offered to adults with IgG4-Related disease
Disease control ApprovedThis expanded access program allows adults with a confirmed diagnosis of IgG4-related disease to request the investigational drug AMG 335, also known as UPLIZNA. IgG4-related disease is a rare condition where the immune system causes inflammation and swelling in organs. The progr…
Sponsor: Amgen • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combos tested to improve lymphoma control in younger patients
Disease control OngoingThis study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Early phase 1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New MS drug trial targets kids: could ocrelizumab slow relapses?
Disease control OngoingThis study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Double punch: CAR-T cells followed by antibodies may boost lymphoma remission
Disease control OngoingThis study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo aims to stop lymphoma relapse after powerful treatments
Disease control OngoingThis phase II trial tests whether combining pembrolizumab (Keytruda) and tazemetostat can help prevent aggressive B-cell lymphoma from returning after patients have already received a stem cell transplant or CAR-T cell therapy. The study enrolls 32 adults and will measure how lon…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Blood-Cleaning device hit its plasma exchange targets?
Disease control OngoingResearchers review past therapeutic plasma exchange treatments performed with the multiFiltratePRO, a device that cleans blood outside the body. The study looks at records from people with autoimmune diseases who weighed at least 40 kg and received this treatment between 2019 and…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Outpatient immunotherapy tested for hard-to-treat lymphomas
Disease control OngoingResearchers are testing an experimental drug called epcoritamab in adults with diffuse large B-cell lymphoma or classic follicular lymphoma that has come back or stopped responding to earlier treatments. The trial gives the drug as an injection under the skin in increasing doses,…
Phase 2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug cocktail aims to beat aggressive lymphoma
Disease control OngoingThis phase 3 trial is testing whether adding the drug glofitamab to a standard chemotherapy combination (Pola-R-CHP) works better than the standard combo alone for people with untreated large B-cell lymphoma. About 1,130 participants will receive either the new combination or the…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug hope for kids with rare Muscle-Weakening disease
Disease control OngoingThis study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…
Phase 2/3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target lymphoma after transplant
Disease control OngoingThis study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back. After a stem cell transplant, patients receive genetically modified immune cells designed to recognize and attack cancer cells. The goal is to see if this approach is safe a…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New CAR-T therapy targets Hard-to-Treat cancers
Disease control PausedThis early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New dye could spare thousands of women from unnecessary lymph node removal
Disease control PausedThis study tests a new dye called Magtrace that stays in the lymph nodes for weeks. For women with non-invasive breast cancer (DCIS) having a mastectomy, this dye may allow doctors to safely delay lymph node removal until after the breast tissue is checked for hidden invasive can…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control PausedThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Blood cancer combo trial pulled before it even started
Disease control CancelledThis study was designed to test whether adding olutasidenib to standard chemotherapy drugs could help control certain blood cancers in people with an IDH1 gene mutation. The trial was withdrawn before enrolling any participants, so no results are available.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an antibody drug boost standard chemotherapy against an aggressive blood cancer?
Disease control OngoingDiffuse large B-cell lymphoma is an aggressive cancer of immune cells called B cells. This phase 3 trial tests whether adding an experimental antibody drug called epcoritamab to the standard R-CHOP chemotherapy combination improves disease control compared with R-CHOP alone. Abou…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an antibody drug boost transplant results in relapsed myeloma?
Disease control OngoingResearchers are testing whether adding the antibody drug isatuximab to dexamethasone before and after an autologous stem cell transplant helps patients with relapsed multiple myeloma. About 50 adults who already had a transplant and later relapsed will receive three cycles of isa…
Phase 2 • Sponsor: EMN Trial Office S.r.l. Impresa Sociale • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control OngoingThis phase 2 trial is testing whether combining two drugs, mosunetuzumab and zanubrutinib, can help people with follicular lymphoma whose cancer has returned or stopped responding to previous treatment. The study will enroll 56 participants and measure how many achieve a complete…
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill could tame severe ulcerative colitis Flare-Ups
Disease control OngoingThis study tests an experimental drug called SAR441566 in about 204 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. Participants will receive either the drug or a placebo for up to 52 weeks t…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New targeted radiation therapy aims to improve stem cell transplants for tough myeloma
Disease control CancelledThis early-phase trial tests a new approach for high-risk multiple myeloma: a radioactive antibody that targets cancer cells, followed by a donor stem cell transplant. The antibody delivers radiation directly to myeloma cells, while chemotherapy and low-dose radiation help prepar…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThis phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at lea…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for lymphoma patients: zanubrutinib combo enters phase 3 trial
Disease control OngoingThis phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New stem cell transplant trial aims to control tough lymphoma
Disease control OngoingThis study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control By invitation onlyThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control OngoingThis study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
Disease control OngoingResearchers are testing whether deucravacitinib, a daily oral drug, can reduce joint swelling, tenderness, and skin symptoms in people with active psoriatic arthritis. The trial enrolls adults who have not taken biologic drugs for their arthritis or who previously received a TNF …
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New cocktail of cancer drugs tested for tough leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolera…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New pill could tame ulcerative colitis Flare-Ups
Disease control OngoingThis study tests an experimental oral drug called GS-5290 (tilpisertib fosmecarbil) in 176 adults with moderate to severe ulcerative colitis. Participants are randomly assigned to receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can improve s…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug joins standard chemotherapy in fight against B-Cell lymphoma
Disease control OngoingResearchers are testing whether adding an experimental drug called rocbrutinib to standard R-CHOP chemotherapy is safe and shows early signs of helping adults newly diagnosed with certain B-cell non-Hodgkin lymphomas. The trial enrolls about 112 participants who have not yet rece…
Phase 1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingThis study tests a combination of three drugs—gilteritinib, venetoclax, and azacitidine—in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a FLT3 gene change. Participants are older or have other health issues that prevent them from receiv…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody tested against aggressive blood cancer
Disease control OngoingResearchers are testing an experimental drug called epcoritamab in Chinese adults with B-cell non-Hodgkin lymphoma. The trial gives epcoritamab alone or combines it with standard chemotherapy drugs (R-CHOP or R2). The main goals are to check safety and see how well the cancer res…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immunotherapy injection tested against Hard-to-Treat childhood lymphoma
Disease control OngoingStandard treatment cures most children with aggressive mature B-cell lymphomas, but those whose cancer returns or resists therapy have few options. This phase 1b trial tests epcoritamab, an experimental immunotherapy given as an injection under the skin, in children and young adu…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for Crohn's: experimental drug aims to heal the gut
Disease control OngoingThis study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. Participants will receive different doses of the drug or a placebo for up to 52 weeks to see if it reduces gut inflammation and improves symptoms. The goal is to find a s…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for tough leukemia? early trial of ABBV-453 begins
Disease control OngoingThis early-phase study tests an experimental drug called ABBV-453, given with another cancer drug (obinutuzumab), in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. About 60 participa…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for ITP patients: experimental drug aims to boost platelets
Disease control OngoingThis phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study mea…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for tough lymphoma: targeted drug combo shows promise in early trial
Disease control OngoingThis phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug DFV890 takes on Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new drug called DFV890 in about 62 adults with low-risk myelodysplastic syndromes, low-risk chronic myelomonocytic leukemia, or high-risk clonal cytopenia of undetermined significance. The main goals are to check the drug's safety, find the best dos…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new drug trio overcome venetoclax resistance in leukemia?
Disease control By invitation onlyResearchers are testing whether a combination of homoharringtonine, lisaftoclax, and azacitidine can help adults with acute myeloid leukemia (AML) whose disease stopped responding to venetoclax-based treatment. The trial plans to enroll 73 participants and give them the three dru…
Phase 2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a cancer drug help patients with rare gene changes?
Disease control OngoingThis phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cell therapy aims to stop blood cancer relapse in tough-to-treat patients
Disease control CancelledThis early-phase study tests a new cell therapy called BSB-2002 in adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goals are to check safety and see if it can prevent the cancer from coming …
Phase 1 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New weekly shot aims to tame Sjögren's Flare-Ups
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in 180 adults with moderate to severe Sjögren's disease. Participants receive either the drug or a placebo as a weekly injection under the skin for 24 weeks. The goal is to see if the drug can reduce overall disease activity …
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo therapy aims to boost lymphoma treatment
Disease control OngoingThis phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could dead donors provide Life-Saving bone marrow?
Disease control OngoingThis early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…
Phase 1/2 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for tough myeloma: drug plus radiation trial launches
Disease control PausedThis early-phase trial tests whether combining talquetamab (a targeted antibody drug) with radiation therapy can safely treat multiple myeloma that has spread to organs or soft tissues. About 20 adults with this hard-to-treat condition will receive radiation to the tumor site plu…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could stem cell islets end daily insulin shots?
Disease control OngoingThis early-phase trial tests VX-264, a therapy made from stem cells that produce insulin, in 7 people with long-standing type 1 diabetes. The goal is to see if it is safe and can help control blood sugar. If successful, it may reduce or replace the need for insulin injections.
Phase 1/2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot
Disease control OngoingResearchers are testing whether a combination of daratumumab, pomalidomide and dexamethasone can help people whose multiple myeloma has come back and carries a genetic change called del(17p). This change, found in about 10% of patients at diagnosis, makes the cancer harder to tre…
Phase 2 • Sponsor: Fondazione EMN Italy Onlus • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill hopes to tame rare blood cancer in japanese patients
Disease control OngoingThis study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control OngoingThis study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…
Phase 3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New injection aims to tame lupus when standard treatments fail
Disease control OngoingThis early-stage study tests an injection called GC012F in 20 adults with refractory systemic lupus erythematosus (SLE) — a type of lupus that hasn't responded to standard treatments. The goal is to see if the therapy is safe and can reduce disease activity. Participants receive …
Phase 1/2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo shows promise against blood cancer
Disease control OngoingThis study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug may extend remission after CAR-T in myeloma
Disease control PausedThis phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare leukemia: Anthracycline-Free combo trial launches
Disease control OngoingThis study tests a combination of drugs (venetoclax plus azacitidine, decitabine, or cytarabine) without traditional anthracycline chemotherapy in 40 adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFβ::MYH11-positive). The goal is to see if thi…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kids with rare kidney disease: crovalimab trial underway
Disease control OngoingThis phase 3 trial tests crovalimab in 41 children with atypical hemolytic uremic syndrome (aHUS), a rare disease that causes blood clots and kidney damage. The drug is given first through a vein, then as a shot under the skin every four weeks. The goal is to see if it can stop d…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare leukemia: targeted pill tackles relapse
Disease control OngoingThis study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New arthritis drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug c…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Experimental combo aims to outsmart relapsed blood cancers
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody drug shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New shot shows promise against tough lymphoma in japanese study
Disease control OngoingThis trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail aims to boost lymphoma treatment
Disease control OngoingThis study tests adding vorinostat, a drug that blocks enzymes cancer cells need to grow, to the standard R-CHOP chemotherapy and antibody therapy for people with newly diagnosed advanced diffuse large B-cell lymphoma (DLBCL). The trial has two parts: first, finding the safest do…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New insulin icodec study aims to improve diabetes control
Disease control OngoingThis study observes how well insulin icodec controls blood sugar in 245 people with type 1 diabetes who have never used it before. Participants take the insulin as prescribed by their doctor, and researchers track changes in HbA1c and treatment satisfaction over about 22 to 30 we…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can adding another drug improve MDS treatment?
Disease control OngoingThis study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill combo aims to tame bone marrow cancer
Disease control OngoingThis early-phase study tests whether adding a new drug called pelabresib to the standard treatment ruxolitinib is safe and helpful for Japanese adults with myelofibrosis, a type of bone marrow cancer. Only 6 people will take part, and the main goal is to check for side effects an…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called SEA-CD70, alone or with standard drugs azacitidine and venetoclax, in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goal is to check safety and find the right dose. About 178 participants will b…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Gene fix trial aims to tame rare immune disease
Disease control By invitation onlyThis study tests a gene therapy for people with X-linked chronic granulomatous disease (X-CGD), a genetic condition that weakens the immune system and leads to severe infections. Researchers take the patient's own stem cells, add a working copy of the faulty gene, and return the …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
One-Time infusion aims to build cancer killers inside the body
Disease control OngoingThis early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…
Phase 1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Targeted drug afatinib tested against HER2-Mutated tumors
Disease control OngoingThis phase II trial tests the drug afatinib in 40 people with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer growth. The study aims to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a short pill course save hand function in advanced MS?
Disease control OngoingThis UK trial tests whether cladribine tablets, taken for just 8-10 days a year over two years, can slow the loss of hand function in people with advanced multiple sclerosis (MS). The study includes 204 participants with significant disability (EDSS 6.5-8.5). Half receive cladrib…
Phase 2/3 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Engineered immune cells take on rare autoimmune disease in kids
Disease control PausedThis early-stage trial tests whether a type of immunotherapy called CAR-T cells can safely treat children with severe systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. The treatment involves collecting the child's own immune cells, engine…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo shows promise for aggressive lymphoma patients
Disease control OngoingThis study tests whether adding the targeted drug ibrutinib to standard chemotherapy (R-CHOP) helps people with a hard-to-treat type of lymphoma called ABC-DLBCL. About 75 adults aged 18-65 with a poor prognosis will receive the combo for 6 cycles, then take ibrutinib alone for 1…
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New eczema drug combo enters early human testing
Disease control OngoingThis early-stage trial is testing a combination of two experimental drugs, APG777 and APG990, in 86 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drugs move through the body, comparing them to the existing treatment Dupixe…
Phase 1 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug hope for rare kidney disease: daratumumab trial launches
Disease control OngoingThis study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce …
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Engineered t cells take aim at Hard-to-Treat leukemia
Disease control OngoingThis early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
CAR-T cells take on progressive MS: early trial launches
Disease control OngoingThis early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo takes aim at brain lymphoma
Disease control OngoingThis phase 2 trial tests a combination of six drugs (TEDDI-R) in 48 adults with aggressive B-cell lymphoma that has spread to the central nervous system. The goal is to see if this mix can control the cancer better than current treatments. Participants receive the drugs in 21-day…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a cell injection calm the gut after a stem cell transplant?
Disease control By invitation onlyThis trial tests whether adding an experimental cell therapy called Amimaitosai to standard steroids can treat severe gut inflammation that sometimes occurs after a stem cell transplant. The study enrolls people with blood cancers who develop this condition, called gastrointestin…
Early phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Promising drug cocktail targets tough blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who haven't had treatment before. The goal is to find the safest dose and see if the combo can shrink or control …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New study aims to help smokers with HIV kick the habit for good
Disease control OngoingThis study tests whether a smoking cessation medication (varenicline) combined with tools to help people stick with treatment can improve quit rates for smokers living with HIV. About 340 participants will be followed for 6 months to see if they stop smoking, confirmed by breath …
Phase 3 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cocktail aims to tame rare brain cancer
Disease control OngoingThis early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could a One-Time immune cell treatment tame severe vasculitis?
Disease control OngoingThis Phase 2 trial tests a one-time infusion of rapcabtagene autoleucel, a CAR-T cell therapy made from a patient's own immune cells, against standard treatments for severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). About 126 adults aged 18-7…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New Three-Drug cocktail shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study is testing a combination of three drugs (alisertib, bortezomib, and rituximab) in about 24 people with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of the…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a targeted drug hit the mark in Hard-to-Treat blood cancers?
Disease control OngoingThis trial tests an experimental drug called IMGN632 in people with certain blood cancers, including acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The drug is designed to find and attack cancer cells that carry a protein called CD123 on their surface. R…
Phase 1/2 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Engineered immune cells take on tough Muscle-Weakening disease
Disease control OngoingThis early-stage trial is testing a new treatment called YTB323 for people with generalized myasthenia gravis that hasn't responded to standard therapies. YTB323 is a CAR-T cell therapy, meaning a patient's own immune cells are modified in a lab to better attack the disease. The …
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill aims to keep ulcerative colitis in check for a year
Disease control OngoingThis study looks at the safety and effectiveness of Velsipity tablets taken daily for up to 52 weeks by people with moderate to severe ulcerative colitis. About 553 participants will be followed in real-world medical settings. The goal is to see if the drug can help control sympt…
Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can an experimental antibody boost chemo's power against lymphoma?
Disease control OngoingThis Phase 2 trial tests whether adding an experimental antibody called JS203 to standard chemotherapy regimens can shrink tumors in people with B-cell non-Hodgkin's lymphoma, a cancer of immune cells. The study enrolls adults aged 18 to 80 whose cancer cells carry the CD20 marke…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Lupus drug anifrolumab put to the test in Real-World study
Disease control OngoingThis study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
Disease control OngoingThis early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug cocktail aims to stall Lymphoma's return
Disease control OngoingThis Phase 3 trial tests whether adding tafasitamab to lenalidomide and rituximab helps people with relapsed follicular or marginal zone lymphoma live longer without their cancer worsening. About 654 participants receive either the three-drug combo or lenalidomide plus rituximab …
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo offers hope for older AML patients who Can't tolerate chemo
Disease control OngoingThis study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant myeloma
Disease control PausedThis study tests whether adding the drug iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has relapsed or become resistant. About 88 participants will receive either the new combo or the standard combo…
Phase 1/2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New lupus drug RO7507062 enters first human safety trial
Disease control OngoingThis early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug aims to stop transplant complications in blood cancer patients
Disease control CancelledThis phase II trial tests whether adding the drug axatilimab to standard care can prevent graft-versus-host disease (GVHD) in 72 blood cancer patients receiving a stem cell transplant. GVHD occurs when donor cells attack the patient's body, causing serious symptoms. Axatilimab is…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug combo in one liposome beat AML at first try?
Disease control OngoingThis pilot trial tests whether Vyxeos, a liposomal formulation combining two chemotherapy drugs, can effectively treat newly diagnosed low- or intermediate-risk acute myeloid leukemia (AML) in adults aged 18 to 70. Some participants also receive Mylotarg, an antibody-drug conjuga…
Phase 2 • Sponsor: Shaare Zedek Medical Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Triple-Drug attack aims to wipe out blood cancer cells
Disease control OngoingThis Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could removing certain immune cells prevent a deadly transplant complication?
Disease control OngoingThis study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell tr…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug GS-0151 tested for rheumatoid arthritis in early trial
Disease control OngoingThis early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cocktail aims to boost remission in rare blood cancer
Disease control OngoingThis phase II trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) improves outcomes for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 63 participants will receive the three-drug combo…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a lower dose of a leukemia drug keep the disease in check?
Disease control OngoingThis study tests whether reducing the dose of the cancer drug radotinib can still control chronic myeloid leukemia in its early phase while possibly easing side effects. Adults newly diagnosed with this blood cancer take a lower dose twice daily for up to a year. Researchers meas…
Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a newer drug outperform the standard for chronic myeloid leukemia?
Disease control OngoingThis phase III trial compares two oral drugs, radotinib and imatinib, in adults newly diagnosed with chronic myeloid leukemia in its chronic phase. Researchers want to see if radotinib, taken twice daily, achieves a deeper molecular response at 12 months than imatinib, taken once…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug CND261 tested for rheumatoid arthritis relief
Disease control OngoingThis early-stage study tests a new drug, CND261, in 47 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that it might…
Phase 1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new knee implant design offer better Long-Term relief?
Disease control By invitation onlyThis study tests a new total knee replacement system called LinkSymphoKnee, which uses an ultra-congruent bearing surface designed to provide stability and mimic natural knee movement. Researchers will enroll 600 adults aged 18 to 79 who need a knee replacement due to osteoarthri…
Sponsor: LinkBio Corp. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Bubble boy disease gets a gene fix: new trial offers hope
Disease control By invitation onlyThis study tests a new gene therapy for X-linked severe combined immunodeficiency (X-SCID), a rare immune disorder. Doctors take a person's own stem cells, fix a faulty gene using a technique called base editing, and return the cells to the body. The goal is to rebuild the immune…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a drug combo boost red blood cells in bone marrow disease?
Disease control OngoingThis phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can these pills save Insulin-Making cells in newly diagnosed type 1 diabetes?
Disease control OngoingThis phase 2 trial tests two oral drugs, abrocitinib and ritlecitinib, in 78 people aged 12-35 who were diagnosed with type 1 diabetes within the last 100 days. The goal is to see if these JAK inhibitors can help preserve the body's ability to produce insulin, measured by a stimu…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New cell therapy YTB323 targets MS that breaks through strongest drugs
Disease control OngoingThis early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug duo aims to keep leukemia in check longer
Disease control OngoingThis study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which com…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a simple shot replace IV drips for blood cancer patients?
Disease control OngoingThis study tests if a shot under the skin works as well as an IV infusion for a multiple myeloma drug combination. About 531 adults with relapsed or hard-to-treat myeloma are taking part. The goal is to see if the shot gives similar cancer-fighting results and is easier for patie…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
MS treatment showdown: does starting strong early prevent disability?
Disease control OngoingThis trial compares two treatment strategies for people with relapsing-remitting multiple sclerosis: starting with high-efficacy drugs early versus starting with standard first-line therapies and switching if needed. The study involves 900 participants across multiple sites and t…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New insulin pump system put to the test in 400-Person safety trial
Disease control OngoingThis study is checking if a new insulin pump (NMX8) and continuous glucose monitor (DS5/Simplera Sync) are safe for people with type 1 or type 2 diabetes. About 400 participants, ages 7 to 85, will first wear the sensor for up to 40 days, then use the pump for about 90 days while…
Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New 'Sandwich' strategy aims to stop leukemia relapse
Disease control OngoingThis study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), th…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can an enzyme blocker boost leukemia chemotherapy?
Disease control OngoingThis phase 1 trial tests whether adding the experimental drug calaspargase pegol-mknl to standard chemotherapy can safely help adults with newly diagnosed acute myeloid leukemia (AML). Researchers aim to find the highest tolerable dose and watch for side effects. They will also t…
Phase 1 • Sponsor: West Virginia University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to put mantle cell lymphoma into deep remission
Disease control OngoingThis phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hip implant aims to cut repeat surgeries
Disease control OngoingThis study is testing a new hip implant called the OR3O Dual Mobility System in 177 people who need hip replacement surgery. The goal is to see if the implant is safe and lasts longer without needing another surgery. Researchers will follow participants for up to 10 years to chec…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy could tame tough lupus
Disease control OngoingThis study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a One-Time immune cell infusion help older leukemia patients avoid harsh chemo?
Disease control OngoingThis early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infus…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Phase 4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug stop smoldering myeloma from becoming active cancer?
Disease control OngoingThis phase 2 trial tests whether the drug elranatamab can help people with high-risk smoldering multiple myeloma, a condition where abnormal plasma cells are present but have not yet caused active disease. About 50 adults with this condition will receive elranatamab as a subcutan…
Phase 2 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Precision radiation may make stem cell transplants safer for leukemia patients
Disease control OngoingThis study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome. Instead of radiating the whole body, the new method targets only the bone marrow and lymph nodes, which may reduce damage to healthy organs. The goa…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can early MS patients pause treatment? new trial seeks answers
Disease control OngoingThis study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could a One-Time cell therapy ease myasthenia gravis? new trial launches
Disease control OngoingThis phase 3 study tests an experimental treatment called Descartes-08 for adults with generalized myasthenia gravis, a condition causing muscle weakness. The therapy uses modified immune cells (mRNA CAR T-cells) to target the disease. About 100 participants will receive either t…
Phase 3 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare blood disorder: drug targets overactive immune cells
Disease control OngoingThis phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Gene therapy tackles HIV and lymphoma in one shot
Disease control OngoingThis early study tests whether giving gene therapy after standard chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds anti-HIV genes to the patient's own blood stem cells, aiming to help the body fight HIV. Only 3 participants were enroll…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Weekly insulin shot could replace daily shots for type 1 diabetes
Disease control OngoingThis study compares a new insulin that is injected once a week (insulin icodec) to a standard daily insulin (insulin glargine) in about 877 adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar just as well as the daily one. Participants will …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Phase 2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart chemotherapy outsmart resistant T-Cell cancers?
Disease control OngoingThis trial tests an experimental drug called OBI-3424 in people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has returned or not responded to treatment. The drug is designed to become active mainly inside cancer cells that produce a specific enzy…
Phase 1/2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot aims to restore skin color in vitiligo patients
Disease control OngoingThis early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo. The main goal is to see if the drug is safe when given as a shot under the skin. Researchers will also look for early signs that it might help bring back skin color. The study lasts 84 weeks, inc…
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can Blood-Based injections realign the jaw joint?
Disease control OngoingThis trial compares two injection treatments for a common jaw joint problem where the disc slips out of place but returns, causing pain and clicking. One treatment uses a concentrate from the patient's own blood, called platelet-rich fibrin, while the other uses a sugar solution.…
Phase 2 • Sponsor: Cairo University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New study tests belimumab to tame early lupus
Disease control OngoingThis study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Double immune attack: can two drugs save Insulin-Making cells in new diabetes?
Disease control OngoingThis study tests whether giving two immune-calming drugs (rituximab followed by abatacept) can better preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes, compared to rituximab alone. About 74 participants aged 8 to 45 will receive the drug …
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a protein boost immune recovery after myeloma transplant?
Disease control OngoingThis trial tests whether adding a protein called CYT107 to the standard treatment for multiple myeloma helps the immune system recover faster after a stem cell transplant. The standard treatment includes a chemotherapy drug called melphalan and the transplant itself. Researchers …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a psychedelic help break the cannabis habit?
Disease control OngoingThis phase 2 trial tests whether psilocybin, the active compound in magic mushrooms, combined with psychotherapy can help adults with moderate to severe cannabis use disorder reduce or stop their cannabis use. Participants receive two doses of psilocybin alongside motivational en…
Phase 2 • Sponsor: McMaster University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThis study tests whether guselkumab, given as a shot under the skin, can help people with moderate to severe Crohn's disease achieve remission and heal their gut lining. About 350 adults who have not responded well to other treatments will receive either guselkumab or a placebo. …
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThis large study tests whether guselkumab, an injected drug, can control symptoms and heal the gut lining in people with moderate to severe Crohn's disease. About 1,400 participants will receive guselkumab, an existing treatment (ustekinumab), or a placebo. The goal is to see if …
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
CAR-T therapy takes on standard drugs in Late-Stage myeloma trial
Disease control OngoingThis phase 3 trial tests whether a one-time infusion of cilta-cel, a CAR-T cell therapy, works better than standard drug combinations (PVd or DPd) for people with multiple myeloma that has come back and no longer responds to lenalidomide. About 419 participants will be randomly a…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill could tame tough psoriasis
Disease control OngoingThis phase 3 study tests an experimental oral drug, JNJ-77242113, in about 731 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is …
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug guselkumab shows promise for ulcerative colitis in large trial
Disease control OngoingThis study tests guselkumab, a drug that targets inflammation, in over 1,000 people with moderate to severe ulcerative colitis. Participants receive either guselkumab or a placebo to see if the drug can improve symptoms and lead to remission. The goal is to find a new treatment o…
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Phase 3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Which MS treatment strategy preserves the brain better?
Disease control OngoingThis trial asks whether starting with highly effective MS drugs right away is better than starting with milder drugs and switching to stronger ones only if needed. Researchers will follow about 800 adults with relapsing-remitting MS for several years, using MRI scans and disabili…
Phase 4 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for anemia patients: drug may cut need for blood transfusions
Disease control OngoingThis study tests a drug called luspatercept in people with anemia caused by myelodysplastic syndromes (MDS) or beta-thalassemia who need regular blood transfusions. The goal is to see if the drug is safe and can reduce the number of transfusions needed. About 85 participants in I…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New telemedicine approach targets alcohol use in HIV patients
Disease control OngoingThis study tests whether a telemedicine program that combines brief counseling with cognitive-behavioral therapy can help people with HIV reduce unhealthy alcohol use and improve their overall health. About 308 participants in Alabama will receive either the combined program or b…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Lymphoma patients may get a simpler shot option
Disease control OngoingThis phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New shot could help celiac patients who still suffer despite strict diet
Disease control OngoingThis study tests a drug called amlitelimab in adults with celiac disease who still have symptoms even after following a gluten-free diet for at least a year. About 229 participants will receive either the drug or a placebo as a shot under the skin for up to 28 weeks. The goal is …
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kids with stubborn psoriasis: drug trial shows promise
Disease control OngoingThis study tests a drug called guselkumab in children aged 6 to 17 with chronic plaque psoriasis. The goal is to see if it safely clears skin patches better than a placebo or another treatment. About 120 participants will receive injections and be monitored for 16 weeks.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail shows promise in battling blood cancer
Disease control OngoingThis phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy (chlorambucil plus obinutuzumab) for adults with chronic lymphocytic leukemia (CLL) who have not yet been treated. The main goal is to se…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New CAR-T therapy aims to wipe out myeloma cells
Disease control OngoingThis study is testing a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma. The goal is to see if it can reduce cancer cells to undetectable levels (called minimal residual disease negative). About 210 participants who have already tried oth…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New biologic mirikizumab put to the test against standard therapies for IBD
Disease control By invitation onlyThis study compares the real-world effectiveness of mirikizumab against standard biologic therapies for adults with ulcerative colitis or Crohn's disease. Researchers will track whether mirikizumab reduces the need for extra medical care, like emergency visits or treatment change…
Phase 4 • Sponsor: Specialty Networks Research. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kids with severe colitis: drug trial shows promise
Disease control OngoingThis study tests a drug called golimumab in children aged 2-17 with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (symptom relief) within 6 week…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug overcome a tough leukemia mutation?
Disease control OngoingThis trial tests whether asciminib, a drug taken twice daily, can reduce leukemia burden in people with chronic phase chronic myeloid leukemia (CML) who have a specific T315I mutation. The study enrolls 50 adults in Germany, including those who had a stem cell transplant. The mai…
Phase 2 • Sponsor: Thomas Ernst, PD Dr. med. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new drug regimen beat the standard for stem cell transplant complications?
Disease control OngoingThis trial tests whether a drug called cyclophosphamide (PTCY) can prevent graft-versus-host disease (GVHD) better than the current standard, ATG, in patients receiving stem cell transplants from unrelated donors. GVHD is a serious complication where donor immune cells attack the…
Phase 3 • Sponsor: DKMS gemeinnützige GmbH • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a daily inhaled protein restore lung function in a rare autoimmune disease?
Disease control OngoingThis trial tests whether inhaling molgramostim—a lab-made version of a protein that helps lung cells clear out protein buildup—can improve lung function in adults with autoimmune pulmonary alveolar proteinosis (aPAP). In this condition, the immune system blocks a key signal, caus…
Phase 3 • Sponsor: Savara Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a blood pressure pill shield blood vessels from heart attacks?
Disease control OngoingThis trial tests whether sparsentan, a tablet that blocks a chemical called endothelin and lowers blood pressure, can improve blood vessel function and reduce stiffness in people with ANCA-associated vasculitis. Vasculitis is an autoimmune disease that damages blood vessels and r…
Phase 2 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Seaweed extract may soothe inflamed guts — trial puts it to the test
Disease control By invitation onlyThis trial asks whether a supplement made from brown algae, called fucoidan, can improve gut health in people with mild to moderate ulcerative colitis. Participants will take fucoidan or a placebo alongside their usual medication for 12 weeks. Researchers will measure changes in …
Phase 1/2 • Sponsor: Allama Iqbal Medical College • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted drug outperform chemo for a common blood cancer?
Disease control OngoingThis phase 3 trial compares three treatment approaches for people with previously untreated chronic lymphocytic leukemia (CLL): a standard chemo-immunotherapy (obinutuzumab plus chlorambucil), a newer targeted drug (acalabrutinib) combined with obinutuzumab, and acalabrutinib alo…
Phase 3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can telemedicine bring IV antibiotics home?
Disease control OngoingThis trial tests a new model where patients with infections receive intravenous antibiotics at home instead of staying in the hospital. Nurses from a municipal response team visit the patient, while hospital doctors oversee the treatment remotely using telemedicine and welfare te…
Sponsor: Helse Møre og Romsdal HF • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Two-Drug attack outsmart resistant leukemia?
Disease control OngoingThis early-stage trial is testing whether adding an experimental drug called iadademstat to the approved leukemia drug gilteritinib can help people with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The study focuses on patients …
Phase 1 • Sponsor: Oryzon Genomics S.A. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a drug duo keep High-Risk blood cancers at bay after transplant?
Disease control OngoingThis early-phase trial is exploring whether combining two drugs, selinexor and azacitidine, can help prevent relapse in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who carry a TP53 mutation and have already undergone a stem cell transplant…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Could a personalized diet tame rheumatoid arthritis and protect the heart?
Disease control By invitation onlyThis study tests whether a personalized diet, based on the latest Nordic Nutrition Recommendations, can reduce disease activity and cardiovascular risk in people newly diagnosed with rheumatoid arthritis. About 150 participants will be randomly assigned to either a diet following…
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Four-Drug cocktail erase traces of Hard-to-Treat leukemia?
Disease control OngoingThis phase 2 trial is testing whether a sequence of four drugs—bendamustine, obinutuzumab, zanubrutinib, and venetoclax—can eliminate minimal residual disease in people with relapsed or refractory chronic lymphocytic leukemia (CLL). The study enrolls about 42 adults whose CLL has…
Phase 2 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Gut bacteria may predict who benefits from prebiotics in ulcerative colitis
Disease control CancelledThis trial tests whether a prebiotic supplement can ease symptoms in people with mild ulcerative colitis, a chronic inflammatory bowel disease. Participants will take either the prebiotic or a placebo for eight weeks. The study aims to see if certain gut bacteria patterns can pre…
Sponsor: Wageningen University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a B-Cell blocker tame lupus?
Disease control OngoingThis phase 2 trial is testing whether an experimental drug called obexelimab can safely reduce disease activity in people with systemic lupus erythematosus (SLE). The study enrolls about 190 adults aged 18 to 70 with active lupus. Participants are randomly assigned to receive eit…
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug combo push CML into deep remission?
Disease control OngoingThis phase 2 trial is testing whether adding the experimental drug asciminib to standard treatments (imatinib, nilotinib, or dasatinib) can achieve deeper molecular responses in adults newly diagnosed with chronic-phase chronic myeloid leukemia (CML). Participants receive one of …
Phase 2 • Sponsor: University of Jena • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug keep Crohn's disease in check?
Disease control OngoingThis clinical trial is testing whether risankizumab, an experimental drug, can safely and effectively maintain remission in people with moderate to severe Crohn's disease who have already responded to initial treatment. Participants will receive either risankizumab or a placebo f…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
Disease control CancelledThis study tests whether giving the drug anakinra early can prevent severe cytokine release syndrome (CRS) in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) who are receiving CAR-T cell therapy. Participants receive anakinra at the first sign of fever,…
Phase 1/2 • Sponsor: Kevin McNerney • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
MS drug ocrelizumab gets a Needle-Free makeover: new shot form tested
Disease control OngoingThis early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThis trial compares the drug ruxolitinib against the best available standard treatments for people with high-risk polycythemia vera (PV) or essential thrombocythemia (ET), two rare blood cancers that cause overproduction of blood cells and can lead to clots, bleeding, and severe …
Phase 2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Triple-Drug cocktail tame resistant myeloma?
Disease control OngoingThis trial is testing whether a combination of three drugs—ixazomib, pomalidomide, and dexamethasone—can help people with multiple myeloma that has relapsed or become resistant after prior treatments like daratumumab, lenalidomide, and bortezomib. The study will measure how long …
Phase 2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted pill boost Chemotherapy's punch against lymphoma?
Disease control OngoingThis trial is testing whether adding the experimental drug tazemetostat to the standard R-CHOP chemotherapy regimen can improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL) or high-risk follicular lymphoma. The study has two parts: first, to find…
Phase 1/2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering th…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted drug boost the fight against an aggressive blood cancer?
Disease control OngoingThis trial is testing whether adding the targeted drug acalabrutinib to the standard CHOP-R chemotherapy regimen can improve outcomes for people newly diagnosed with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). Richter's syn…
Phase 2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug reduce bloodletting for polycythemia vera?
Disease control CancelledThis trial investigates whether ropeginterferon alfa-2b can help people with polycythemia vera, a condition where the body makes too many red blood cells. The study will compare the drug to standard care, which includes phlebotomy (removing blood) and aspirin. About 70 adults wit…
Phase 4 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a PET-MRI tracer reveal where CAR-T cells go in myeloma?
Disease control OngoingThis phase 1 trial tests whether a special imaging tracer can track CAR-T cells in people with extramedullary myeloma, a type of myeloma that forms tumors outside the bone marrow. Participants receive cilta-cel, a CAR-T therapy targeting the BCMA protein on myeloma cells, along w…
Phase 1 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?
Disease control OngoingThis study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how m…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new drug tame vasculitis with fewer side effects?
Disease control OngoingThis study tracks the safety of avacopan, a medication for ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. Researchers will compare side effects like liver injury, heart problems, serious infections, and cancer in people taking avacopan ve…
Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
Disease control OngoingThis study tests whether a six-month course of dupilumab can calm the immune system enough for patients with severe olive pollen asthma to then benefit from standard allergy immunotherapy. Researchers will use advanced molecular profiling to understand how the treatment restores …
Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a biologic drug outperform standard therapy for a rare blood cancer?
Disease control OngoingThis phase 3 trial compares the biologic drug P1101 (ropeginterferon alfa-2b) against the standard drug anagrelide in people with essential thrombocythemia, a rare blood cancer that causes too many platelets. The study enrolls adults who have not responded well to the first-line …
Phase 3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Digital dashboard aims to transform diabetes care for kids
Disease control By invitation onlyThis study tests whether a digital platform called Haibu Diabetes helps children with type 1 diabetes manage their condition better. The platform collects health data from devices and shares it with patients, caregivers, and doctors through a single dashboard. Researchers will co…
Sponsor: University of British Columbia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can pressurized oxygen boost cord blood transplants?
Disease control OngoingThis study tests whether giving patients hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) after an umbilical cord blood stem cell transplant helps the donated stem cells grow faster. The trial enrolls people with blood cancers like leukemia or lymphoma who lack …
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug D-2570 aims to quiet Flare-Ups in ulcerative colitis
Disease control OngoingThis study tests whether an experimental drug called D-2570 can help people with moderately to severely active ulcerative colitis achieve remission. About 120 adults will receive either D-2570 or a placebo daily for 12 weeks. The main goal is to see if more people on D-2570 reach…
Phase 2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Gene therapy offers hope for 'Bubble Boy' disease without a donor
Disease control PausedThis trial tests a gene therapy for infants under 2 years old with RAG1-deficient severe combined immunodeficiency (SCID), a life-threatening condition where the immune system barely works. The therapy uses the child's own blood stem cells, modified with a corrected gene, to try …
Phase 1/2 • Sponsor: Videja B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Targeted drug aims to clear hidden leukemia before transplant
Disease control OngoingThis study tests whether the targeted drug inotuzumab ozogamicin can eliminate minimal residual disease (MRD) in adults with B-cell acute lymphoblastic leukemia (ALL) before they receive a stem cell transplant. Participants have either Philadelphia chromosome-positive or -negativ…
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a drug free myelofibrosis patients from frequent blood transfusions?
Disease control OngoingThis phase 3 study tests whether the drug luspatercept can help people with myelofibrosis-related anemia become independent of red blood cell transfusions. Participants are adults with myelofibrosis who are already taking a JAK inhibitor and need regular transfusions. The study c…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Four-Drug cocktail aims to crush myeloma before transplant
Disease control OngoingThis phase 3 trial tests whether adding the targeted antibody isatuximab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can achieve deeper remissions in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Particip…
Phase 3 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Simple cord milking procedure could protect newborn brains after difficult births
Disease control OngoingThis trial tests whether a quick procedure called umbilical cord milking—pushing blood from the cord into the baby before clamping—can improve brain development in newborns who are limp or not breathing well at birth. The study follows over 3,400 infants from the earlier CORDMILK…
Sponsor: Nemours Children's Clinic • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to outsmart recurring lymphoma
Disease control OngoingThis phase 3 trial tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) helps adults with follicular lymphoma that has returned or not responded to previous treatment. Participants receive either the standard therapy alone or …
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug duo aims to tackle rare leukemia
Disease control By invitation onlyThis phase 2 trial is testing a combination of two drugs, rituximab and zanubrutinib, in people with hairy cell leukemia or its variant. The goal is to see if this treatment can shrink or eliminate the cancer. Participants take zanubrutinib pills daily and receive rituximab infus…
Phase 2 • Sponsor: Bnai Zion Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a 4-Minute chat rival a Dietitian's hour for heart health?
Disease control OngoingThis study tests whether a short, standardized 4-minute heart-healthy talk is as effective as a full 60-minute personalized session with a dietitian for lowering LDL cholesterol and improving diet. Participants are adults aged 30–80 with rheumatoid arthritis, psoriatic arthritis,…
Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a Once-Daily steroid pill improve blood sugar control in Dual-Disease patients?
Disease control CancelledThis trial tests whether taking hydrocortisone once a day (as a dual-release pill) leads to more stable blood sugar levels compared to the standard three-times-a-day regimen in adults who have both insulin-treated diabetes and Addison's disease. Participants will try both schedul…
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Four-Drug cocktail aims to halt smoldering myeloma before it strikes
Disease control OngoingThis phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…
Phase 2 • Sponsor: Omar Nadeem, MD • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingThis study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Phase 1/2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Suicide Gene-Equipped t cells aim to make stem cell transplants safer
Disease control OngoingThis trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for myeloma patients with kidney failure: targeted drug tested in dialysis patients
Disease control OngoingThis study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Childhood leukaemia trial seeks best chemo cocktail
Disease control OngoingThis trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo aims to boost survival in older AML patients
Disease control OngoingThis phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …
Phase 3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could MRI make CT scans obsolete for thymoma patients?
Diagnosis OngoingThis study compares MRI scans to standard CT scans for staging thymoma, a rare chest tumor. Researchers want to see if MRI can detect tumor spread just as well or better, without using radiation. Forty adults with newly diagnosed or recurrent thymoma will undergo both scans befor…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can PET scans reveal hidden brain inflammation in MS?
Diagnosis By invitation onlyResearchers at Mayo Clinic are testing whether advanced PET and MRI brain scans can measure inflammation in people with multiple sclerosis and other inflammatory demyelinating diseases. The study includes about 200 participants, both patients and healthy controls. Participants re…
Phase 2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a One-Stop clinic solve the mystery of functional disorders?
Diagnosis OngoingFunctional somatic disorders cause persistent physical symptoms that doctors cannot explain by other diseases. The DISTRESS trial evaluates a new clinic where internal medicine doctors, trained to recognize these disorders, examine patients and provide guidance to their general p…
Sponsor: Regionshospitalet Silkeborg • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Glow-in-the-Dark mouth scans could catch cancer early
Diagnosis OngoingThis study tests whether special lights and cameras can help find early signs of mouth cancer in people at high risk. About 338 participants with precancerous spots or conditions like Fanconi anemia will have their mouths examined with fluorescence imaging, which makes abnormal c…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
AI reads heart ultrasound at the bedside: a test for faster detection of weak heart pumping
Diagnosis By invitation onlyThis study tests whether a machine-learning system can accurately interpret focused cardiac ultrasound images taken at the point of care, such as in an emergency room or clinic. About 3,000 adults who need a heart ultrasound will have their images analyzed by the AI, and the resu…
Sponsor: Truway Health, Inc. • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Can a new PET tracer light up brain inflammation?
Diagnosis OngoingThis trial tests an experimental imaging tracer called [11C]-CS1P1, which is designed to attach to a protein involved in brain inflammation. The study will first check the tracer's safety and how it moves through the body in healthy volunteers, then compare its signals in people …
Sponsor: Tammie L. S. Benzinger, MD, PhD • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
Can a Light-Based device spot dangerous infection risk without a blood draw?
Diagnosis OngoingThis trial evaluates a new device called PointCheck that aims to detect severe neutropenia—a dangerous drop in infection-fighting white blood cells—without needing a blood sample. The study includes about 210 people with diffuse large B-cell lymphoma or multiple myeloma who are r…
Sponsor: Leuko Labs, Inc. • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Can a single platform predict your risk for multiple chronic diseases?
Diagnosis By invitation onlyThis pilot study is testing whether the ADEN platform can accurately identify people at risk for heart disease, respiratory problems, cancer, autoimmune conditions, and frailty. Researchers will compare the platform's risk ratings to those made by doctors. If it works, the platfo…
Sponsor: Unidad de Investigación Genética Molecular • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention OngoingThis large phase 3 trial is testing whether a new oral pill called MK-8527, taken just once a month, can prevent HIV infection as well as the standard daily PrEP pill. About 4,390 people at risk of HIV will be randomly assigned to receive either the monthly pill or daily Truvada …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Village health workers lead new HIV prevention effort in lesotho
Prevention CancelledThis study tests a new program where trained village health workers use tablet-based tools to provide HIV prevention services, including PrEP and emergency PEP, to people at high risk in rural Lesotho. About 380 participants will be enrolled to see if this approach increases mont…
Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can cutting alcohol help stop HIV? vietnam trial tests clinic strategies
Prevention OngoingThis study looks at how to best help HIV clinics in Vietnam offer a short alcohol counseling program to patients who drink heavily. The goal is to reduce risky drinking and lower the chance of spreading HIV. Over 3,200 people living with HIV and clinic staff are taking part to se…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
New hope for stem cell patients: drug may stop debilitating chronic GVHD
Prevention PausedThis early-stage trial tests whether the drug ruxolitinib can prevent chronic graft-versus-host disease (cGVHD) in 42 adults who had a stem cell transplant for blood cancer. Doctors use a blood test to find patients at high risk for cGVHD and then give them ruxolitinib to block t…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Can a common antiplatelet drug replace warfarin after APS-Related stroke?
Prevention OngoingAntiphospholipid syndrome (APS) raises the risk of blood clots and strokes, and doctors often prescribe warfarin to prevent another stroke. Warfarin requires frequent blood tests and carries bleeding risks, especially for younger patients. This trial compares clopidogrel-based an…
Phase 4 • Sponsor: Seoul National University Hospital • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
New drug aims to stop dangerous gut infection from returning
Prevention OngoingThis study tests an experimental drug called LMN-201 to see if it can prevent C. difficile infection from coming back after standard antibiotic treatment. About 375 adults with a recent C. diff infection will receive either LMN-201 or a placebo. The main goal is to see if more pe…
Phase 2/3 • Sponsor: Lumen Bioscience, Inc. • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Banking on health: savings accounts may cut HIV risk in kenyan men
Prevention OngoingThis study tests whether offering lottery-based rewards for saving money can help Kenyan men reduce behaviors that raise their risk for HIV and other STIs. About 1,500 men aged 18-39 who drink alcohol and have paid for sex in the past will be split into two groups. One group gets…
Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Sep 12, 2026 00:00 UTC
-
Early Gluten-Free diet or probiotics: a new strategy to prevent celiac disease?
Prevention OngoingResearchers are testing whether a gluten-free diet during the first three years of life, or daily probiotic supplements, can prevent celiac disease in children with a high genetic risk. The trial enrolls infants before they start eating gluten and randomly assigns them to one of …
Sponsor: Lund University • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Can we catch type 1 diabetes before it strikes?
Prevention By invitation onlyThis study tests whether screening children with a high genetic risk for type 1 diabetes, along with regular follow-up and family education, leads to an earlier diagnosis of the disease. Researchers will track 600 children to see if this approach prevents severe symptoms and diab…
Sponsor: Lund University • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Can a switch to goat milk formula prevent baby eczema?
Prevention OngoingThis trial compares two types of infant formula to see if one lowers the chance of developing eczema, also called atopic dermatitis. Researchers will enroll over 2,000 healthy full-term babies and feed them either a formula made from whole goat milk or one made from cow's milk. T…
Sponsor: Dairy Goat Co-operative (N.Z.) Limited • Aim: Prevention
Last updated Aug 29, 2026 00:00 UTC
-
Smartphone app could help breast cancer survivors avoid painful arm swelling
Prevention OngoingThis study tests whether a mobile application can help breast cancer survivors prevent lymphedema, a common and often permanent swelling of the arm after surgery. Participants who had breast cancer surgery at least one month ago will be randomly assigned to use the app or receive…
Sponsor: Inonu University • Aim: Prevention
Last updated Jul 16, 2026 00:00 UTC
-
Online course aims to boost diet and Self-Care for MS and fatigue patients
Symptom relief OngoingThis study is testing whether an online course can help people with multiple sclerosis, long COVID, fibromyalgia, or cancer-related fatigue adopt healthier diets and self-care habits. Researchers will measure changes in quality of life, fatigue, and mental health. The goal is to …
Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Diet showdown: could paleo or keto diets ease MS symptoms?
Symptom relief OngoingThis study tests whether two special diets—a modified Paleolithic elimination diet and a time-restricted ketogenic diet—can improve quality of life, fatigue, and mood in 162 people with relapsing-remitting multiple sclerosis. Participants are assigned to one of the diets or stand…
Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Exercise and diet may ease fatigue in CLL patients
Symptom relief OngoingThis study looks at whether exercise and weight management can help reduce fatigue in people who have had chronic lymphocytic leukemia (CLL). About 30 adults aged 18-85 with CLL will take part. Participants will be randomly assigned to start the program right away or after a wait…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a robotic exoskeleton rebuild arm strength after Guillain-Barré?
Symptom relief OngoingGuillain-Barré syndrome can leave people with weak arms and hands, making daily tasks hard. This trial tests whether adding robot-assisted arm training to usual therapy helps adults in the sub-acute phase of recovery. Participants use the Armeo Power 2 exoskeleton for 20 sessions…
Phase 4 • Sponsor: I.R.C.C.S. Fondazione Santa Lucia • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Could a new cycling style help MS patients walk better and feel less tired?
Symptom relief OngoingThis study tests a new type of cycling called eccentric cycling for people with multiple sclerosis. Researchers want to see if it improves muscle strength, walking ability, fatigue, and quality of life better than standard cycling. Sixty adults with MS who can walk independently …
Sponsor: University of Liege • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Could a wearable nerve stimulator help MS patients walk more freely?
Symptom relief By invitation onlyThis trial tests a wearable device that uses mild electrical pulses to stimulate the leg muscles of people with multiple sclerosis who have foot drop. The goal is to see if using the device for several months improves walking quality, physical activity, and participation in daily…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can a Job-Focused rehab program keep arthritis patients employed?
Symptom relief OngoingPeople with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis often struggle to stay in work. This trial tests a 6-month vocational rehabilitation program called WORK-ON, which includes a coordinating occupational therapist, group sessions with peers, and ind…
Sponsor: The Danish Center for Expertise in Rheumatology • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New app aims to bridge depression care gap for MS patients
Symptom relief OngoingThis study tests a smartphone app called MS CATCH that lets people with multiple sclerosis regularly report their mood to their neurologist. The goal is to improve how doctors screen and treat depression in MS. About 100 adults with MS and mild-to-moderate depression are taking p…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can better sleep ease Crohn's symptoms? new study investigates
Symptom relief OngoingThis study looks at whether treating insomnia can help people with Crohn's disease feel better, including reducing pain and inflammation. About 83 adults with mild to moderate Crohn's and insomnia will receive a remote sleep treatment. The main goal is to see if the approach is p…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can treating the mind help control diabetes? new study tests integrated care
Symptom relief OngoingThis study tests whether adding mental health care to standard diabetes treatment improves mood and blood sugar control in adults with type 1 diabetes. Eighty participants will be randomly assigned to usual care or a collaborative care model that includes a behavioral health cons…
Sponsor: Emory University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Green tea compounds could soothe radiation burns in cancer care
Symptom relief By invitation onlyThis Phase 3 trial tests whether catechins (compounds found in green tea) given as a pill or spray can prevent or treat skin damage caused by radiation therapy. About 162 cancer patients will receive either catechins or a placebo, alongside standard care. The goal is to see if th…
Phase 3 • Sponsor: CARLOS FRANCISCO SAAVEDRA GARCIA • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
A personal nurse and a plan: could this ease the daily burden of arthritis?
Symptom relief OngoingThis trial tests a six-month program where a coordinating rheumatology nurse helps people with inflammatory arthritis set goals and plan actions to manage their condition. Participants also get access to physiotherapy, occupational therapy, and social work support as needed. The …
Sponsor: The Danish Center for Expertise in Rheumatology • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a Nine-Week group program help blood cancer patients grow through trauma?
Symptom relief OngoingResearchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…
Sponsor: University of West Attica • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Could a simple drink help clear confusion in hospitalized seniors?
Symptom relief OngoingThis study tests a proprietary amino acid drink given twice daily for up to 4 days to older adults (60+) hospitalized with infections who have delirium. 20 participants get the drink, 20 get standard care, and 20 non-delirious controls are observed. The goal is to see if the drin…
Sponsor: University of Arkansas • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief OngoingThis study tests an experimental drug called APG777 in 470 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. The goal is to see if the drug safely reduces skin redness, itching, and rash. Participants receive either APG777 or a placebo fo…
Phase 2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Could online therapy ease the swelling of breast cancer lymphedema?
Symptom relief OngoingThis trial tests whether a live online exercise and self-drainage program can reduce arm swelling in women with breast cancer-related lymphedema. Researchers will compare women who join live video sessions with a therapist to those who follow the same program at home using a broc…
Sponsor: Istanbul University • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
2,000 MS patients sought for landmark fatigue study
Symptom relief By invitation onlyThis study tests two online programs designed to help people with multiple sclerosis (MS) understand and manage their fatigue. Researchers will enroll 2,000 adults with MS across the U.S., including veterans, and compare the programs to usual care alone. The goal is to find pract…
Sponsor: Accelerated Cure Project for Multiple Sclerosis • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Exercise may ease IBD symptoms in children, new study hopes to prove
Symptom relief OngoingThis study explores whether physical activity and fitness can reduce inflammation and improve quality of life in children aged 6 to 17 with Crohn's disease or ulcerative colitis. Researchers will track 100 participants over time and test a 12-week supervised exercise program. The…
Sponsor: Universidad Complutense de Madrid • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Can a cancer drug beat CLL fatigue? small trial hopes to find out
Symptom relief OngoingThis phase II trial tests whether ruxolitinib (Jakafi) can reduce fatigue in people with chronic lymphocytic leukemia (CLL) who are not yet ready for standard treatment. Ten participants will take the drug and report their fatigue levels using a simple questionnaire. The goal is …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Virtual Nurse-Led program aims to boost purpose in women with MS
Symptom relief OngoingThis study tests whether a six-week, nurse-led virtual group program can help adult women with Multiple Sclerosis (MS) find more meaning and purpose in life, and improve their quality of life. Participants attend weekly online group sessions focused on reflection and values explo…
Sponsor: Texas Woman's University • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Oxygen chamber treatment tested for long COVID fatigue relief
Symptom relief OngoingThis study is testing whether hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) can improve symptoms like fatigue and brain fog in people with post-COVID syndrome. About 40 adults with long COVID will receive the treatment. The main goal is to see if a la…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New digital coaching aims to ease cancer pain and cut opioid risks
Symptom relief OngoingThis study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New allergy shot aims to tame dust mite misery
Symptom relief OngoingThis early-stage trial tests a new biologic drug called ASP2390, given as a skin injection, in 28 adults with house dust mite allergies. The main goal is to check safety and how the immune system responds, not yet whether it works. If successful, it could lead to a new way to eas…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Home telerehab may keep MS balance gains going after hospital therapy
Symptom relief OngoingThis pilot trial tests whether people with multiple sclerosis can safely and satisfactorily use a telemedicine platform for balance rehabilitation at home. After completing intensive in-hospital rehabilitation, participants either follow a 12-week home telerehabilitation program …
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Promising drug may ease painful genital psoriasis
Symptom relief OngoingThis study tests an injected drug called tildrakizumab for people with moderate to severe genital psoriasis. About 206 adults will receive either the drug or a placebo to see if it clears skin and reduces itching. The goal is to improve comfort and quality of life in this sensiti…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Custom insoles may steady the steps of MS patients — a trial puts them to the test
Symptom relief OngoingThis trial tests whether custom-designed sensorimotor insoles, worn daily for six months, can improve balance and walking in people with multiple sclerosis. Fifty adults with MS (mild to moderate disability) will be randomly assigned to receive the insoles or continue their usual…
Sponsor: University of Salamanca • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can video coaching help ease arthritis symptoms?
Symptom relief OngoingThis study tests whether a home-based exercise program guided by online videos can improve symptoms and quality of life in people with axial spondyloarthritis, a type of arthritis affecting the spine. Participants follow video exercises for 3 months, and researchers compare their…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Spinal zaps at home could restore hand control in MS
Symptom relief By invitation onlyThis pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New hope for myeloma patients: switching to ixazomib after failed treatments?
Knowledge-focused OngoingThis study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a g…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Major study tracks Real-World MG care in china
Knowledge-focused OngoingThis study follows about 1,200 people with myasthenia gravis (MG) across China to understand how the disease is treated in real-world clinics. Researchers will track symptoms, daily living abilities, quality of life, and healthcare use every 6 months until 2027. The goal is to le…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
NIH opens screening study to find candidates for blood disorder research
Knowledge-focused By invitation onlyThis study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New tools could help doctors predict who will respond to chronic GVHD therapies
Knowledge-focused OngoingThis study involves 383 people who have chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers are developing and testing new ways to measure whether a treatment is working, including a symptom-based activity index and a score that predicts long-term s…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Pregnancy to adolescence: what shapes a Child's health?
Knowledge-focused OngoingProject Viva is a long-term study that follows more than 2,000 mother-child pairs from pregnancy into the child's teenage years. Researchers measure children's growth, metabolic risk factors, and brain development, and they track mothers' weight and children's asthma symptoms. Th…
Sponsor: Harvard Pilgrim Health Care • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind family blood cancer clusters
Knowledge-focused OngoingThis long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused By invitation onlyThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can Real-World data show how well multiple sclerosis patients stick with ofatumumab?
Knowledge-focused OngoingResearchers are studying how people with relapsing multiple sclerosis use ofatumumab in everyday practice in Germany and Japan. The study looks at insurance claims from about 5,000 adults to see how many stay on the treatment and how regularly they take it. It also tracks how oft…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New brain scan may predict chemo brain in young leukemia patients
Knowledge-focused PausedThis study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can wearable sensors and walking tests reliably track nerve damage?
Knowledge-focused OngoingResearchers are checking whether tests of muscle strength, walking, balance, and fine motor skills give consistent results in people with polyneuropathy. About 520 adults with various forms of nerve damage, plus healthy volunteers, take part. Participants complete physical tests,…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can a simple arm measurement help prevent lymphedema pain?
Knowledge-focused OngoingThis study asks breast cancer patients about their thoughts on screening for lymphedema, a common side effect where the arm becomes swollen and painful after treatment. Researchers use a device called a perometer to measure arm size before and after surgery. The goal is to see if…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
University health survey aims to uncover hidden struggles of students and staff
Knowledge-focused OngoingThis study is a health check for students at Constructor University Bremen and employees at HAW-Hamburg. Researchers will use surveys and interviews to measure loneliness, anxiety, stress, and health habits. The goal is to understand what affects wellbeing and find ways to suppor…
Sponsor: Jacobs University Bremen gGmbH • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
One bite of gluten: scientists track the immune alarm in celiac disease
Knowledge-focused By invitation onlyResearchers at Boston Children's Hospital are studying how the immune system reacts after a single oral dose of gluten powder. The study includes people with celiac disease and healthy controls, all of whom follow a gluten-free diet before the test. By measuring blood levels of i…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
New drug RO7875913 tested in healthy volunteers for first time
Knowledge-focused OngoingThis early-stage trial is testing a new drug called RO7875913 in 40 healthy volunteers to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo. The study aims to find the right dose for future trials, but offers no direct treatme…
Phase 1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can your Baby's surroundings trigger asthma? scientists investigate
Knowledge-focused OngoingThis study follows 499 children from birth to age 6-7 to understand how early-life factors like allergens, pollution, and microbes may lead to asthma and allergies. Parents with asthma or hay fever are included. No treatments or changes are made—just observation to uncover root c…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
When the immune system Can't fight back: tracking three respiratory viruses
Knowledge-focused OngoingResearchers are reviewing medical records from a large hospital network in Buenos Aires to understand what happens to adults with severely weakened immune systems after they catch RSV, influenza, or SARS-CoV-2. The study covers 350 patients and looks at how sick they were at diag…
Sponsor: Hospital Italiano de Buenos Aires • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can a handoff plan help teens with chronic illness take charge of their care?
Knowledge-focused OngoingResearchers are testing a transition program for 17-year-olds with type 1 diabetes, asthma, or obesity who are preparing to move from pediatric to adult healthcare. The program includes a consultation with the teen and family, a solo visit where the teen completes a readiness che…
Sponsor: Universiteit Antwerpen • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Lupus care under the microscope: new registry tracks Real-World treatment in kazakhstan
Knowledge-focused OngoingThis study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are b…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Web tool aims to empower rare cancer patients in genomic choices
Knowledge-focused OngoingThis study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can amniotic cell secretions shield nerves in ALS and MS?
Knowledge-focused OngoingResearchers are collecting blood and skin samples from people with ALS, people with MS, and healthy volunteers. They turn skin cells into stem cells and grow them into 3D organoids that mimic the brain and spinal cord. The goal is to see whether secretions from human amniotic mes…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Real-World data may reveal how acalabrutinib performs in chinese blood cancer patients
Knowledge-focused By invitation onlyThis observational study tracks about 160 Chinese adults with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who take acalabrutinib as part of their normal care. Researchers will record how the drug is used, including doses and com…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Hidden muscle loss in Sjögren's syndrome: a new study looks for answers
Knowledge-focused OngoingThis study examines whether women with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth, also experience muscle loss, a condition called sarcopenia. Researchers will measure muscle strength, muscle mass, and physical performance in 120 participants…
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New blood test could spot cancer return after transplant
Knowledge-focused OngoingThis study is testing a new blood test called AlloHeme that measures how much of a patient's own cells remain after a bone marrow transplant. The goal is to see if this test can predict whether the cancer (acute leukemia or myelodysplastic syndrome) will come back. About 307 adul…
Sponsor: CareDx • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Massive russian CLL study tracks Real-World treatments
Knowledge-focused OngoingThis study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatme…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
New skin scanner could reveal hidden changes in eczema treatment
Knowledge-focused OngoingThis study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…
Sponsor: Hôpitaux Drôme Nord • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
HIV patients over 75: are too many pills harming healthy aging?
Knowledge-focused PausedThis study looks at people with HIV who are 75 or older and take at least five medications regularly. Researchers want to understand how this 'polypharmacy' affects healthy aging and quality of life. They will interview participants and review their medical records to count medic…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Massive medicare study aims to improve joint replacement safety
Knowledge-focused OngoingThis study looks at records from over 500,000 Medicare beneficiaries with rheumatoid arthritis or ankylosing spondylitis who had major orthopedic procedures like joint replacements or spine surgery between 1999 and 2015. Researchers want to understand how often complications happ…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Will a new drug form work the same? study tests two versions of SKI-O-703
Knowledge-focused OngoingThis study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The r…
Phase 1 • Sponsor: Oscotec Inc. • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Cord milking may save newborn brains: major trial underway
Knowledge-focused OngoingThis study looks at over 3,400 newborns who are not vigorous at birth (between 35 and 42 weeks). Doctors want to see if milking the umbilical cord (pushing blood into the baby) before clamping it leads to fewer cases of brain injury or death compared to clamping the cord right aw…
Sponsor: Nemours Children's Clinic • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists collect skin cells to pave way for future immune disease cures
Knowledge-focused By invitation onlyThis study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
No new treatment, just Check-Ups: gene therapy patients monitored for 15 years
Knowledge-focused By invitation onlyThis study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Brain shrinkage as a crystal ball for MS progression?
Knowledge-focused By invitation onlyThis observational study follows about 2,400 people with relapsing-remitting multiple sclerosis (MS) across Germany for up to six years. It asks whether loss of volume in the thalamus—a deep brain region—tracks with worsening disability, measured by the EDSS scale. Using standard…
Sponsor: Jung Diagnostics GmbH • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can a radioactive tracer reveal hidden lung scarring?
Knowledge-focused OngoingThis study tests whether a radioactive tracer called 68Ga-FAPi-46 can light up areas of scarring (fibrosis) in the lungs of people with interstitial lung disease. Participants receive the tracer and undergo a PET/CT scan to see where it collects. The goal is to understand how the…
Early phase 1 • Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Are clinics missing advanced HIV cases? a new study investigates
Knowledge-focused PausedThis study looks at how often CD4 cell counts are measured when adults in Zambia begin or restart antiretroviral therapy (ART) after a long break. The goal is to see how many people have advanced HIV disease and whether low testing rates prevent proper care. Researchers will asse…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Can your genes predict wood smoke harm?
Knowledge-focused PausedThis study explores why some people develop airway inflammation after breathing wood smoke while others do not. Researchers will expose healthy adults and those with mild allergic asthma to controlled wood smoke particles and measure immune cell changes in the lungs. They will al…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Can Real-World data improve diabetes care in pregnancy?
Knowledge-focused OngoingThis study gathers real-world information from pregnant women with type 1 diabetes in the United States to understand how they manage their condition. Participants share data from their continuous glucose monitors and insulin pumps, and complete online surveys. The goal is to lea…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
A simple hospital checklist could flag hidden malnutrition in kids with IBD
Knowledge-focused OngoingThis study tests whether a standard nutrition screening tool, called PYMS, can accurately identify children with Crohn's disease or ulcerative colitis who are at risk of malnutrition. Researchers will use the tool on 2,000 children aged 4–18 with IBD in outpatient and inpatient c…
Sponsor: University of Glasgow • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can Early-Life factors steer preterm and term infant health?
Knowledge-focused OngoingThis study follows mother-infant pairs from birth to 24 months to see how early nutrition, environmental exposures, and family factors relate to growth, development, and allergies in preterm and term infants. Researchers will use questionnaires and biological samples to examine h…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can a biologic drug tame juvenile arthritis in kids?
Knowledge-focused CancelledThis study follows children aged 6 to 17 with active juvenile enthesitis-related or psoriatic arthritis who are being treated with secukinumab. Researchers will track how long children stay on the drug, how much their symptoms improve, and whether they achieve remission. The goal…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Real-World dupixent: does it live up to the hype for eczema?
Knowledge-focused OngoingThis study follows about 955 people aged 12 and older who are starting treatment with Dupixent (dupilumab) for atopic dermatitis, commonly known as eczema. The goal is to see how the drug performs in everyday clinical practice, not just in controlled trials. Researchers will trac…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
A 20-Minute walk: a new way to boost brain health in MS?
Knowledge-focused OngoingThis study explores whether a brief, moderate-intensity walk can alter brain function and blood flow in people with multiple sclerosis. Participants will undergo MRI scans before and after either treadmill or overground walking at a brisk pace. The goal is to see if even a single…
Early phase 1 • Sponsor: Kessler Foundation • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can we predict Crohn's damage before it happens? a Long-Term study aims to find out
Knowledge-focused OngoingThis study follows people newly diagnosed with Crohn's disease for up to five years to see how the condition damages the bowel over time. Researchers will use imaging scans and other tests to track disease progression and understand how different treatments affect long-term outco…
Sponsor: GLSMED Learning Health S.A. • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Could the key to better CAR-T therapy lie in the gut?
Knowledge-focused OngoingThis study explores whether the types of bacteria living in a person's gut can influence how well CAR-T cell therapy works for diffuse large B-cell lymphoma. Researchers will track changes in the gut microbiome of 69 patients from before treatment up to 18 months afterward. The g…
Sponsor: University of Bologna • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Stool test may predict gut healing in ulcerative colitis
Knowledge-focused By invitation onlyThis study is testing whether a simple stool test can predict if the gut lining is healing in people with moderate-to-severe ulcerative colitis who are starting biologic therapy for the first time. Researchers will measure levels of a protein called calprotectin in stool samples …
Sponsor: Tang-Du Hospital • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
MS crystal ball: new biomarkers aim to predict disability before it strikes
Knowledge-focused OngoingThis study follows 300 people with multiple sclerosis to see whether advanced MRI scans, eye tests, and blood markers can better predict when disability will worsen. Current tools are not accurate enough to guide early treatment for each individual. The researchers will compare t…
Sponsor: EDMUS Foundation • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Massive MS registry aims to decode why some patients worsen faster than others
Knowledge-focused OngoingThis observational study follows thousands of people with multiple sclerosis (MS) over many years to identify factors that predict how the disease will progress. Researchers collect detailed clinical data, MRI scans, and quality-of-life questionnaires from participants treated at…
Sponsor: EDMUS Foundation • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Study aims to keep workers with chronic illnesses on the job
Knowledge-focused OngoingThis study looks at how chronic noncommunicable diseases like inflammatory bowel disease and breast cancer impact a person's ability to work. Researchers will follow 200 working-age adults for 12 months, collecting data on health, work performance, and well-being. The goal is to …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
New brain scanner could reveal hidden effects of childhood neurological diseases
Knowledge-focused OngoingThis study uses a new, child-friendly brain imaging technique called OPM-MEG to understand how immune-related brain diseases (like autoimmune encephalitis and multiple sclerosis) and other brain conditions affect children aged 2 to 25. Standard scans often miss problems with memo…
Sponsor: Aston University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Digital diary aims to decode painful flares in spine condition
Knowledge-focused OngoingThis study investigates how people with axial spondyloarthritis (axSpA) experience sudden worsening of symptoms, known as flares. Over 12 months, 40 participants use a digital diary to track symptoms, diet, lifestyle, and self-management strategies, and provide blood samples duri…
Sponsor: Royal United Hospitals Bath NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Can a more intense chemo regimen beat aggressive lymphoma?
Knowledge-focused OngoingThis study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a blood test predict lupus flares? new study aims to find out
Knowledge-focused OngoingThis study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…
Phase 3 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Do vaccines still work during lymphoma treatment? new study aims to find out
Knowledge-focused OngoingThis study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Real-World study tracks elidel use in asian kids with eczema
Knowledge-focused OngoingThis study is observing how Elidel cream (pimecrolimus) is actually used in South and East Asian children aged 3 months to 12 years with mild to moderate atopic dermatitis (eczema). Researchers are tracking changes in eczema severity, itching, and sleep loss over the treatment pe…
Sponsor: BGP Products Operations GmbH, a Viatris company • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Massive 30-Year Women's health study reveals hidden disease links
Knowledge-focused OngoingThis long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
HIV treatment showdown: could simpler drug regimens reduce inflammation?
Knowledge-focused OngoingThis study looks at HIV patients over 40 (or those on HIV therapy for over 10 years) who switched to either a three-drug or a two-drug antiretroviral regimen. Researchers will measure markers of inflammation in the blood and track how many patients develop other health conditions…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Do blood transfusions help at the end of life? a study asks patients and staff
Knowledge-focused OngoingThis study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC